Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 60
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Intraepithelial CD15 infiltration identifies high-grade anal dysplasia in people with HIV

  • Burgos, Joaquín|||0000-0001-8445-3047
  • Benítez-Martínez, Aleix
  • Mancebo, Cristina
  • Massana, Núria|||0000-0002-5403-3161
  • Astorga-Gamaza, Antonio|||0000-0002-1276-5276
  • Castellvi, Josep|||0000-0001-5745-9996
  • Landolfi, Stefania|||0000-0002-1059-635X
  • Curran, Adrian|||0000-0002-1263-0814
  • García Pérez, Jorge Néstor|||0000-0003-4986-6094
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Buzón, Maria José|||0000-0003-4427-9413
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
Men who have sex with men (MSM) with HIV are at high risk for squamous intraepithelial lesion (SIL) and anal cancer. Identifying local immunological mechanisms involved in the development of anal dysplasia could aid treatment and diagnostics. Here, we studied 111 anal biopsies obtained from 101 MSM with HIV, who participated in an anal screening program. We first assessed multiple immune subsets by flow cytometry, in addition to histological examination, in a discovery cohort. Selected molecules were further evaluated by immunohistochemistry in a validation cohort. Pathological samples were characterized by the presence of resident memory T cells with low expression of CD103 and by changes in natural killer cell subsets, affecting residency and activation. Furthermore, potentially immunosuppressive subsets, including CD15 + CD16 + mature neutrophils, gradually increased as the anal lesion progressed. Immunohistochemistry verified the association between the presence of CD15 in the epithelium and SIL diagnosis for the correlation with high-grade SIL. A complex immunological environment with imbalanced proportions of resident effectors and immune-suppressive subsets characterized pathological samples. Neutrophil infiltration, determined by CD15 staining, may represent a valuable pathological marker associated with the grade of dysplasia. Assessment of changes in relevant anal dysplasia-associated mucosal immune subsets provides potential targets for immunotherapy and a complementary biomarker for current diagnostics.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  • Jimenez-Leon, Maria Reyes|||0000-0003-2723-319X
  • Gasca-Capote, Carmen|||0000-0002-7211-8599
  • Roca-Oporto, Cristina|||0000-0003-0079-5491
  • Espinosa, Nuria|||0000-0003-2249-2352
  • Sobrino, Salvador
  • Fontillon-Alberdi, Maria|||0000-0003-4031-8067
  • Gao, Ce
  • Roseto, Isabelle
  • Gladkov, Gregory
  • Rivas-Jeremias, Inmaculada
  • Neukam, Karin
  • Sánchez Hernández, José Germán
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Cervera-Barajas, Antonio J.
  • Mesones, Rosario
  • García, Federico
  • Alvarez-Rios, Ana Isabel
  • Bachiller, Sara
  • Vitalle, Joana
  • Perez-Gomez, Alberto
  • Camacho-Sojo, María Inés
  • Gallego, Isabel
  • Brander, Christian|||0000-0002-0548-5778
  • McGowan, Ian
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Yu, Xu
  • Lichterfeld, Mathias
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
BACKGROUND. We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS. Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS. Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION. Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT03577782. FUNDING. This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, "a way to make Europe," research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch Lombarte, Oscar
  • Tarancón Diez, Laura
  • Pedreño Lopez, Nuria
  • Arenas Busto, Miguel
  • Alvaro, Tamara
  • Casado, Concepción
  • Olivares, Isabel
  • Vera, Mar
  • Rodríguez, Carmen
  • del Romero, Jorge
  • López Galíndez, Cecilio
  • Ruiz Mateos, Ezequiel
  • Prado, Julia G.
  • Pernas, María
Background Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. Results In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. Conclusions These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses., Instituto de Salud Carlos III | Ref. PI13/02269, Instituto de Salud Carlos III | Ref. PI17/00164, Instituto de Salud Carlos III | Ref. PI16/0684, Instituto de Salud Carlos III | Ref. PI19/01127, Ministerio de Economía y Competitividad | Ref. RD12/0017/0028, Ministerio de Economía y Competitividad | Ref. RD16/0025/0020, Generalitat de Catalunya | Ref. AGAUR-FI_B 00582, Agencia Estatal de Investigación | Ref. RYC-2015-18241, Agencia Estatal de Investigación | Ref. PID2019-107931GA-I00, Xunta de Galicia | Ref. ED431F 2018/08, Ministerio de Economía y Competitividad | Ref. RD16/0025/0041
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV

  • Corma-Gómez, Anaïs
  • Fernández-Fuertes, Marta
  • García, Estefanía
  • Fernández-López, Rosa
  • Gómez-Ayerbe, Cristina
  • Rivero-Juárez, Antonio
  • Domínguez, Carmen
  • Santos, Marta
  • Viñuela, Laura
  • Palacios, Rosario
  • Real, Luis Miguel
  • Rivero, Antonio
  • Macías, Juan
  • Pineda, Juan A.
  • García, Federico
[Objectives] The aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion., [Methods] This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies., [Results] Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts ≥350 cells/mm3 (95%), 55 of 61 PLWH with 200 to 349 cells/mm3 (90%), and 21 of 33 PLWH with CD4 counts <200 cells/mm3 (64%; p < 0.001). The median log10 IgG neutralization levels were 2.4 IU/mL (Q1–Q3, 1.0–3.1) among PLWH with CD4 counts <200 cells/mm3, 3.1 IU/mL (Q1–Q3, 2.8–3.4) for the 200 to 349 cells/mm3 group, and 3.1 IU/mL (Q1–Q3, 2.7–3.4) for PLWH with CD4 counts ≥350 cells/mm3 (p = 0.016). In the multivariate analysis, CD4 counts ≥350 cells/mm3 (OR: 7.10; 95% CI, 1.91–26.46; p = 0.004) and receiving mRNA-vectored COVID-19 vaccines (OR: 8.19; 95% CI, 3.24–20.70; p ≤ 0.001) were independently associated with a higher probability of response to vaccination., [Discussion] HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell counts <200 cells/μL. Adenoviral-vectored vaccines should be avoided in PLWH whenever possible., This work was supported, in part, by the Spanish Network for AIDS Investigation (www.red.es/redes/inicio; RD16/0025/0040) as part of the Nacional I + D + I, ISCIII Subdirección General de Evaluación and the European Fund for Development of Regions. Juan Antonio Pineda received a research extension grant from the Programa de Intensificación de la Actividad de Investigación del Servicio Nacional de Salud Carlos III. Anaïs Corma-Gómez received a Río..., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)

  • Esteban, Ignasi
  • Pastor-Quiñones, Carmen
  • Usero, Lorena
  • Aurrecoechea, Elena
  • Franceschini, Lorenzo
  • Esprit, Arthur
  • Gelpí, Josep Lluís
  • Martínez-Jiménez, Francisco
  • López-Bigas, Núria
  • Breckpot, Karine
  • Thielemans, Kris
  • Leal, Lorna
  • Gómez, Carmen Elena
  • Sisteré-Oró, Marta
  • Meyerhans, Andreas
  • Esteban, Mariano
  • Alonso, María José
  • García, Felipe
  • Plana, Montserrat
The COVID-19 pandemic has brought significant changes and advances in the field of vaccination, including the implementation and widespread use of encapsidated mRNA vaccines in general healthcare practice. Here, we present two new mRNAs expressing antigenic parts of the SARS-CoV-2 spike protein and provide data supporting their functionality. The first mRNA, called RBD-mRNA, encodes a trimeric form of the virus spike protein receptor binding domain (RBD). The other mRNA, termed T-mRNA, codes for the relevant HLA I and II spike epitopes. The two mRNAs (COVARNA mRNAs) were designed to be used for delivery to cells in combination, with the RBD-mRNA being the primary source of antigen and the T-mRNA working as an enhancer of immunogenicity by supporting CD4 and CD8 T-cell activation. This innovative approach substantially differs from other available mRNA vaccines, which are largely directed to antibody production by the entire spike protein. In this study, we first show that both mRNAs are functionally transfected into human antigen-presenting cells (APCs). We obtained peripheral blood mononuclear cell (PBMC) samples from three groups of voluntary donors differing in their immunity against SARS-CoV-2: non-infected (naïve), infected-recovered (convalescent), and vaccinated. Using an established method of co-culturing autologous human dendritic cells (hDCs) with T-cells, we detected proliferation and cytokine secretion, thus demonstrating the ability of the COVARNA mRNAs to activate T-cells in an antigen-specific way. Interestingly, important differences in the intensity of the response between the infected-recovered (convalescent) and vaccinated donors were observed, with the levels of T-cell proliferation and cytokine secretion (IFNγ, IL-2R, and IL-13) being higher in the vaccinated group. In summary, our data support the further study of these mRNAs as a combined approach for future use as a vaccine., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses

  • Falqui, Michela
  • Perdiguero, Beatriz
  • Coloma, Rocío
  • Albert, Manuel
  • Marcos-Villar, Laura
  • McGrail, Joseph Patrick
  • Sorzano, Carlos Óscar S.
  • Esteban, Mariano
  • Gómez, Carmen Elena
  • Guerra, Susana
The human immunodeficiency virus (HIV), responsible of the Acquired Immune Deficiency Syndrome (AIDS), continues to be a major global public health issue with any cure or vaccine available. The Interferon-stimulated gene 15 (ISG15) encodes a ubiquitin-like protein that is induced by interferons and plays a critical role in the immune response. ISG15 is a modifier protein that covalently binds to its targets via a reversible bond, a process known as ISGylation, which is the best-characterized activity of this protein to date. However, ISG15 can also interact with intracellular proteins via non-covalent binding or act as a cytokine in the extracellular space after secretion. In previous studies we proved the adjuvant effect of ISG15 when delivered by a DNA-vector in heterologous prime-boost combination with a Modified Vaccinia virus Ankara (MVA)-based recombinant virus expressing HIV-1 antigens Env/Gag-Pol-Nef (MVA-B). Here we extended these results evaluating the adjuvant effect of ISG15 when expressed by an MVA vector. For this, we generated and characterized two novel MVA recombinants expressing different forms of ISG15, the wild-type ISG15GG (able to perform ISGylation) or the mutated ISG15AA (unable to perform ISGylation). In mice immunized with the heterologous DNA prime/MVA boost regimen, the expression of the mutant ISG15AA from MVA-Δ3-ISG15AA vector in combination with MVA-B induced an increase in the magnitude and quality of HIV-1-specific CD8 T cells as well as in the levels of IFN-I released, providing a better immunostimulatory activity than the wild-type ISG15GG. Our results confirm the importance of ISG15 as an immune adjuvant in the vaccine field and highlights its role as a potential relevant component in HIV-1 immunization protocols., This research was supported by the Spanish State Research Agency Ministry of Health of Spain, State secretary of R+D and FEDER/FSE, SAF-2017-88089-R, PDC2021-121307-I00 PID2020- 117425RB-C21 to SG and PID2020-117425RB-C22 to CG; by CIBER consortium, Thematic Area in Infectious Diseases: CIBERINFEC (CB21/13/00108) to CG; by Red Temática de Investigación Cooperativa en Salud: Red Española de Investigación en Sida (RIS) RD16/0025/0014 and in part by European HIV Vaccine Alliance (EHVA) grant ID: 681032 to ME., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

  • Perdiguero, Beatriz
  • Pérez, Patricia
  • Marcos-Villar, Laura
  • Albericio, Guillermo
  • Astorgano, David
  • Álvarez, Enrique
  • Sin, Laura
  • Gómez, Carmen Elena
  • García-Arriaza, Juan
  • Esteban, Mariano
Although one member of the poxvirus family, variola virus, has caused one of the most devastating human infections worldwide, smallpox, the knowledge gained over the last 30 years on the molecular, virological and immunological mechanisms of these viruses has allowed the use of members of this family as vectors for the generation of recombinant vaccines against numerous pathogens. In this review, we cover different aspects of the history and biology of poxviruses with emphasis on their application as vaccines, from first- to fourth-generation, against smallpox, monkeypox, emerging viral diseases highlighted by the World Health Organization (COVID-19, Crimean-Congo haemorrhagic fever, Ebola and Marburg virus diseases, Lassa fever, Middle East respiratory syndrome and severe acute respiratory syndrome, Nipah and other henipaviral diseases, Rift Valley fever and Zika), as well as against one of the most concerning prevalent virus, the Human Immunodeficiency Virus, the causative agent of Acquired Immunodeficiency Syndrome. We discuss the implications in human health of the 2022 monkeypox epidemic affecting many countries, and the rapid prophylactic and therapeutic measures adopted to control virus dissemination within the human population. We also describe the preclinical and clinical evaluation of the Modified Vaccinia virus Ankara and New York vaccinia virus poxviral strains expressing heterologous antigens from the viral diseases listed above. Finally, we report different approaches to improve the immunogenicity and efficacy of poxvirus-based vaccine candidates, such as deletion of immunomodulatory genes, insertion of host-range genes and enhanced transcription of foreign genes through modified viral promoters. Some future prospects are also highlighted., We thank various agencies for continuous funding support, such as Fondo COVID-19 grant COV20/00151 [Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)], Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander) and Spanish Research Council (CSIC) grant 202120E079 (to JG-A); Red Sida RD16/0025/0002, CSIC grant 2020E84, La CaixaImpulse grant CF01-00008, Ferrovial and MAPFRE donations (to ME); Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grants PID2020-114481RB-I00 (to JG-A and ME) and PID2020-117425RB-C22 (to CEG); and funds from Centro de Investigacio ́n Biome ́dica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to CEG and JG-A). We have also received funding from the European Commission-Next Generation EU through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). We also acknowledge financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses

  • Usero, Lorena
  • Leal, Lorna
  • Gómez, Carmen Elena
  • Miralles, Laia
  • Aurrecoechea, Elena
  • Esteban, Ignasi
  • Torres, Berta
  • Inciarte, Alexy
  • Perdiguero, Beatriz
  • Esteban, Mariano
  • García, Felipe
  • Plana, Montserrat
The development of new strategies to achieve a functional cure for HIV remains a priority. We tested a novel HIV therapeutic vaccine using unmodified mRNA (TMEP-B) and mRNA modified by 1-methyl-3'-pseudouridylyl (TMEP-Bmod) expressing both a multiepitopic sequences from Gag, Pol, and Nef proteins, including different CD4 and CD8 T-cell epitopes functionally associated with HIV control in transfected monocyte-derived dendritic cells (MDDCs) obtained from HIV infected patients. In vitro assays were used to test the mRNAs alone and in combination with immunomodulator agents, such as the TLR-7 agonist Vesatolimod and the PD-1 antagonist Nivolumab to try to improve HIV-specific cellular immune responses. Combining the mRNAs with the immunomodulators enhanced HIV-specific T-cell responses, together with the secretion of IFNγ, IP10, MIP-1α, and MIP-1β, which are fundamental mediators of viral control. Our data suggest that the mRNA vaccine prototypes TMEP-B and TMEP-Bmod, when combined with Vesatolimod and/or Nivolumab, could achieve functional cure for patients with HIV., This study was partially supported by grants from the Spanish Ministry of Economy (MINECO) (grants: SAF-2017-88089-R and RTI2018-096309-B-I00); the Fondo Europeo para el Desarrollo Regional (FEDER); the SPANISH AIDS Research Network RD16/0025/0002 and RD16/0025/0014- ISCIII-FEDER (RIS); Projects FIS PI18/00699, COV20/00214 and ICI20/00067 financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Union; HIVACAT program; the CERCA Programme/Generalitat de Catalunya SGR 615 and SGR 653; and by the European Commission (grant numbers: FP7-HEALTH-2013-INNOVATION-1 602570-2 and H2020-SC1-2016-2017 (H2020-SC1-2016- RTD) Proposal: 731626-HIVACAR)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant

  • Berenguer, J.
  • Jarrín, I.
  • Pérez-Latorre, L.
  • Hontañón, V.
  • Vivancos, M.J.
  • Navarro, J.
  • Téllez, M.J.
  • Guardiola, J.M.
  • Iribarren, J.A.
  • Rivero-Juárez, A.
  • Márquez, M.
  • Artero, A.
  • Morano, L.
  • Santos, I.
  • Moreno, J.
  • Fariñas, M.C.
  • Galindo, M.J.
  • Hernando, M.A.
  • Montero, M.
  • Cifuentes, C.
  • Domingo, P.
  • Sanz, J.
  • Domíngez, L.
  • Ferrero, O.L.
  • De La Fuente, B.
  • Rodríguez, C.
  • Reus, S.
  • Hernández-Quero, J.
  • Gaspar, G.
  • Pérez-Martínez, L.
  • García, C.
  • Force, L.
  • Veloso, S.
  • Losa, J.E.
  • Vilaró, J.
  • Bernal, E.
  • Arponen, S.
  • Ortí, A.J.
  • Chocarro, Á.
  • Teira, R.
  • Alonso, G.
  • Silvariño, R.
  • Vegas, A.
  • Geijo, P.
  • Bisbe, J.
  • Esteban, H.
  • González-García, J.
Background We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Otros (Other)

Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes

  • Vrancken, B.
  • Cuypers, L.
  • Pérez, A.B.
  • Chueca, N.
  • Anton-Basantas, J.
  • de la Iglesia, A.
  • Fuentes, J.
  • Pineda, J.A.
  • Téllez, F.
  • Bernal, E.
  • Rincón, P.
  • Von Wichman, M.A.
  • Fuentes, A.
  • Vera, F.
  • Rivero-Juárez, A.
  • Jiménez, M.
  • Vandamme, A.M.
  • García, F.
To the Editor: As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.1 Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID), 2 who are at the core of ongoing HCV transmission.3 Macías et al.4 have recently shown in this Journal that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere. As the chronic nature of most HCV infections hampers reliably reconstructing contact networks from patient interviews, virus genetic data can be a valuable alternative source of information for elucidating the geographic history of virus lineages (e.g. [5], [6]). Using such data, we have recently shown that for the most prevalent subtype among PWID in Spain (40%, 7), HCV1a, infections often link to infections abroad – in recent years >50% link to Western European countries, mostly European Union (EU) member states – as opposed to other infections ...
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy

  • Gálvez, Cristina
  • Grau Exposito, Judit
  • Urrea, Victor
  • Clotet, Bonaventura
  • Falcó Ferrer, Vicenç
  • Buzón Gómez, María José
ADN del VIH-1; Cura del VIH-1; Reservorio de VIH-1, HIV-1 DNA; HIV-1 cure; HIV-1 reservoir, ADN del VIH-1; Cura del VIH-1; Reservori del VIH-1, Knowing the mechanisms that govern the persistence of infected CD4+ subpopulations could help us to design new therapies to cure HIV-1 infection. We evaluated the simultaneous distribution of the HIV-1 reservoir in 13 CD4+ subpopulations from 14 HIV-1-infected individuals on antiretroviral therapy to analyze its relationship with HIV-1 transcription, immune activation, and cell proliferation. A unique large blood donation was used to isolate CD4, CD4 resting (CD4r), CD4 activated (CD4a), T naive (TN), T stem cell memory (TSCM), T central memory (TCM), T transitional memory (TTM), T effector memory (TEM), circulating T follicular helper (cTFH), TCD20, TCD32, and resting memory TCD2high (rmTCD2high) cells. HIV-1 DNA measured by droplet digital PCR ranged from 3,636 copies/106 in TTM to 244 in peripheral blood mononuclear cells (PBMCs), with no subpopulation standing out for provirus enrichment. Importantly, all the subpopulations harbored intact provirus by intact provirus DNA assay (IPDA). TCD32, cTFH, and TTM had the highest levels of HIV-1 transcription measured by fluorescent in situ hybridization with flow cytometry (FISH/flow), but without reaching statistical differences. The subpopulations more enriched in provirus had a memory phenotype, were less activated (measured by CD38+/HLA-DR+), and expressed more programmed cell death 1 (PD-1). Conversely, subpopulations transcribing more HIV-1 RNA were not necessarily enriched in provirus and were more activated (measured by CD38+/HLA-DR+) and more proliferative (measured by Ki-67). In conclusion, the HIV reservoir is composed of a mosaic of subpopulations contributing to the HIV-1 persistence through different mechanisms such as susceptibility to infection, provirus intactness, or transcriptional status. The narrow range of reservoir differences between the different blood cell subsets tested suggests limited efficacy in targeting only specific cell subpopulations during HIV-1 cure strategies. IMPORTANCE The main barrier for HIV-1 cure is the presence of latently infected CD4+ T cells. Although various cell subpopulations have been identified as major HIV-1 reservoir cells, the relative contribution of infected CD4 subpopulations in the HIV-1 reservoir remains largely unknown. Here, we evaluated the simultaneous distribution of the HIV-1 reservoir in 13 CD4+ T-cell subpopulations in peripheral blood from HIV-1-infected individuals under suppressive antiretroviral therapy. We found that the HIV-1 reservoir is composed of a mosaic of cell subpopulations, with heterogeneous proviral DNA, HIV-1 transcription, and activation status. Hence, each cell subpopulation contributes to the HIV-1 persistence through different mechanisms such as susceptibility to infection, rates of intact provirus, transcriptional status or half-life. This research provides new insights into the composition of the HIV-1 reservoir, suggesting that, to be effective, eradication strategies must simultaneously target multiple cell subpopulations., This work was sponsored in part by Grifols and by Gilead (GLD17/00204). The funding organizations had no input in the design of the study or in the collection, analyses, and interpretation of the data. Similarly, they played no role in the writing of the manuscript or in the decision to submit the study for publication. J.M.-P. is supported by grant PID2019-109870RB-I00 from the Spanish Ministry of Science and Innovation. J.M.-P. and M.J.B. are supported by the RETIC RD16/0025/0041 and RD16/0025/0007 (cofunded by the European Regional Development Fund/European Social Fund). M.J.B. is supported by grant RTI2018-101082-B-I00 (MINECO/FEDER) and by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). C.G. was supported by the Ph.D. fellowship of the Spanish Ministry of Education, Culture, and Sport (FPU15/03698).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Intraepithelial CD15 infiltration identifies high-grade anal dysplasia in people with HIV

  • Mancebo Pérez, Cristina
  • Massana, Nuria
  • Astorga Gamaza, Antonio
  • Burgos, Joaquin
  • Benítez Martínez, Aleix
  • Castellvi, Josep
  • Landolfi, Stefania
  • Curran, Adrian
  • García Pérez, Jorge N.
  • Buzon, Maria Jose
  • Genescà Ferrer, Meritxell
  • Falcó, Vicenç
Adaptive immunity; Immunology; Infectious disease, Immunitat adaptativa; Immunologia; Malaltia infecciosa, Inmunidad adaptativa; Inmunología; Enfermedad infecciosa, Men who have sex with men (MSM) with HIV are at high risk for squamous intraepithelial lesion (SIL) and anal cancer. Identifying local immunological mechanisms involved in the development of anal dysplasia could aid treatment and diagnostics. Here, we studied 111 anal biopsies obtained from 101 MSM with HIV, who participated in an anal screening program. We first assessed multiple immune subsets by flow cytometry, in addition to histological examination, in a discovery cohort. Selected molecules were further evaluated by immunohistochemistry in a validation cohort. Pathological samples were characterized by the presence of resident memory T cells with low expression of CD103 and by changes in natural killer cell subsets, affecting residency and activation. Furthermore, potentially immunosuppressive subsets, including CD15+CD16+ mature neutrophils, gradually increased as the anal lesion progressed. Immunohistochemistry verified the association between the presence of CD15 in the epithelium and SIL diagnosis for the correlation with high-grade SIL. A complex immunological environment with imbalanced proportions of resident effectors and immune-suppressive subsets characterized pathological samples. Neutrophil infiltration, determined by CD15 staining, may represent a valuable pathological marker associated with the grade of dysplasia., The authors thank the study participants. We would also like to thank Cristina de Dios Conde and Marta Valeri Sala from the Microscopy platform at the High Technology Unit (UAT, VHIR) for excellent technical assistance. This work was primarily supported by grants from the Spanish Health Institute Carlos III (ISCIII, PI16/00736 and PI20/00160) and cofunded by ERDF/ESF, “A way to make Europe”/“Investing in your future.” This work was additionally supported in part by the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007), the Fundació La Marató TV3 (201814-10FMTV3), and the Gilead fellowships GLD18/00008. MJB is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). NM was supported by a PhD fellowship from the VHIR. The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez de Ory, Santiago
  • Ramos, José Tomas
  • Fortuny, Clàudia
  • González-Tomé, María Isabel
  • Mellado, Maria José
  • Moreno, David
  • Frick, Marie Antoinette
Retrospective study; Spanish Paediatric HIV Network; Rates of perinatal HIV, Estudio retrospectivo; Red Española de VIH Pediátrico; Tasas de VIH perinatal, Estudi retrospectiu; Xarxa espanyola de VIH Pediàtrica; Taxes de VIH perinatal, Background: There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods: A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results: A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions: A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact., This work has been partially funded by Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de Salud Carlos III (ISCIII) (RD12/0017/0035, RD12/0017/0037 and RD16/0025/0019), project as part of the Plan R+D+I (2008-2011; 2013-2016) and cofinanced by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER), RISEPICLIN-19/2015, Fondo para la Investigación Sanitaria of the Spanish Ministry of Science and Innovation (FIS PI13/00422, PI16/01863), CYTED (214RT0482) and EPIICAL Project. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. COST CA17140 Cancer Nanomedicine-Front The Bench to Bebside. We thank the Spanish HIV HGM BioBank supported by ISC III project RETIC PT13/0010/0028 and PT17/0015/0042. No funding for this work was received from National Institutes of Health (NIH), Wellcome Trust and Howard Hughes Medical Institute (HHMI)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response

  • Grau Exposito, Judit
  • Navarro Mercadé, Jordi
  • Curran Fàbregas, Adria
  • Planas Ribas, Bibiana
  • Suanzes Diez, Paula
  • Falcó Ferrer, Vicenç
  • Genesca Ferrer, Meritxell
  • Buzón Gómez, María José
  • Astorga Gamaza, Antonio
  • Burgos Cibrian, Joaquin
HIV; Infectious disease; Reservoir, VIH; Malalties infeccioses; Reservori, VIH; Enfermedades infecciosas; Reservorio, Human immunodeficiency virus (HIV) establishes a persistent infection in heterogeneous cell reservoirs, which can be maintained by different mechanisms including cellular proliferation, and represent the main obstacle to curing the infection. The expression of the Fcγ receptor CD32 has been identified as a marker of the active cell reservoirs in people on antiretroviral therapy (ART), but if its expression has any role in conferring advantage for viral persistence is unknown. Here, we report that HIV-infected cells expressing CD32 have reduced susceptibility to natural killer (NK) antibody-dependent cell cytotoxicity (ADCC) by a mechanism compatible with the suboptimal binding of HIV-specific antibodies. Infected CD32 cells have increased proliferative capacity in the presence of immune complexes, and are more resistant to strategies directed to potentiate NK function. Remarkably, reactivation of the latent reservoir from antiretroviral-treated people living with HIV increases the pool of infected CD32 cells, which are largely resistant to the ADCC immune mechanism. Thus, we report the existence of reservoir cells that evade part of the NK immune response through the expression of CD32., This study was supported by the Spanish Secretariat of Science and Innovation and FEDER funds (grants SAF2015-67334-R and RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish “Ministerio de Economia y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI17/01470), GeSIDA and the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 201814-10FMTV3) and the Gilead fellowships GLD19/00084 and GLD18/00008. M.B is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). A.A-G is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016–076382). The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A baseline metabolomic signature is associated with immunological CD4 + T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Mallol, Roger
  • López Dupla, Miguel
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Alba, Verónica|||0000-0002-5925-9573
  • Blanco, Julià|||0000-0002-2225-0217
  • Cañellas, Nicolau
  • Rull, Anna|||0000-0002-8907-7754
  • Leal, Manuel
  • Correig, Xavier|||0000-0002-6902-3054
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Vidal, Francesc|||0000-0002-6692-6186
Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 + T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System

  • Moure, Ricardo
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Villarroya, Joan
  • Gasa, Laura
  • Gallego-Escuredo, José Miguel
  • Quesada-López, Tania|||0000-0002-7818-4351
  • Morón-Ros, Samantha|||0000-0002-6205-2442
  • Maroto, Alberto F.
  • Mateo, Gracia M.
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Girlat, Marta|||0000-0001-7968-4190
Following antiretroviral therapy, HIV-infected patients show increased circulating levels of the antidiabetic hormone fibroblast growth factor 21 (FGF21). In contrast, the expression of the FGF21-obligatory coreceptor β-Klotho (KLB) is reduced in target tissues. This situation is comparable to the FGF21 resistance status observed in obesity and type 2 diabetes. Here, we performed the first systematic study of the effects of distinct members of different antiretroviral drug classes on the FGF21/KLB system in human hepatic, adipose, and skeletal muscle cells. Most protease inhibitors and the nonnucleoside reverse transcriptase inhibitor efavirenz induced FGF21 gene expression. Neither nucleoside reverse transcriptase inhibitors nor the viral entry inhibitor maraviroc had any effect. Among the integrase inhibitors, elvitegravir significantly induced FGF21 expression, whereas raltegravir had minor effects only in adipose cells. In human hepatocytes and adipocytes, known target cells of FGF21 action, efavirenz, elvitegravir, and the lopinavir-ritonavir combination exerted inhibitory effects on KLB gene expression. Drug treatments that elicited FGF21 induction/KLB repression were those found to induce endoplasmic reticulum (ER) stress and oxidative stress. Notably, the pharmacological agents thapsigargin and tunicamycin, which induce these stress pathways, mimicked the effects of drug treatments. Moreover, pharmacological inhibitors of either ER or oxidative stress significantly impaired lopinavir-ritonavir-induced regulation of FGF21, but not KLB. In conclusion, the present in vitro screen study identifies the antiretroviral drugs that affect FGF21/KLB expression in human cells. The present results could have important implications for the management of comorbidities resulting from side effects of specific antiretroviral drugs for the treatment of HIV-infected patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Versatile iron-catechol-based nanoscale coordination polymers with antiretroviral ligand functionalization and their use as efficient carriers in HIV/AIDS therapy

  • Solórzano Rodríguez, Ruben
  • Tort Regàs, Olívia
  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Escribà, Tuixent|||0000-0001-9467-7802
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Arnedo, Mireia|||0000-0001-6248-7780
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Alibés, Ramon|||0000-0002-7997-2691
  • Busqué, Félix|||0000-0001-7566-4264
  • Novio, Fernando|||0000-0002-1517-3612
A novel chemical approach integrating the benefits of nanoparticles with versatility of coordination chemistry is reported herein to increase the effectiveness of well-known HIV antiretroviral drugs. The novelty of our approach is illustrated using a catechol ligand tethered to the known antiretroviral azidothymidine (AZT) as a constitutive building block of the nanoparticles. The resulting nanoscale coordination polymers (NCPs) ensure good encapsulation yields and equivalent antiretroviral activity while significantly diminishing its cytotoxicity. Moreover, this novel family of nanoparticles also offers (i) long-lasting drug release that is dissimilar inside and outside the cells depending on pH, (ii) triggered release in the presence of esterases, activating the antiviral activity in an on-off manner due to a proper chemical design of the ligand and (iii) improved colloidal stabilities and cellular uptakes (up to 50-fold increase). The presence of iron nodes also adds multifunctionality as possible contrast agents. The present study demonstrates the suitability of NCPs bearing pharmacologically active ligands as an alternative to conventional antiretroviral treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status

  • Ceausu, Andra
  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Peraire, Joaquim|||0000-0001-7808-5479
  • López-Dupla, M.
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Vidal-Gonzalez, J.
  • Perpiñán, C.
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Veloso, S.
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Ruiz-Mateos, E.
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Vidal, Francisco|||0000-0001-8089-4945
  • Rull, A.
A relationship between polymorphisms in genes encoding interleukin 7 (IL-7) and its cellular receptor (IL-7R) and antiretroviral therapy (ART)-associated immune recovery in HIV subjects has been previously reported. However, details of this relationship remain unclear, and the association of these polymorphisms with circulating IL-7/IL-7R levels is scarce. Here, we explored whether IL-7/IL-7R axis was associated with quantitative CD4 T-cell recovery in HIV-infected subjects. IL-7/IL-7R polymorphisms were assessed by genotyping, and multiple inheritance models were used to estimate both, their association with low pre-ART CD4 T-cell counts and incomplete immune recovery status after 48 weeks of suppressive ART. Integrated data from genetic variants association and soluble plasma IL-7/IL-7R quantification suggest that IL-7/IL-7R genotype expression could alter the homeostatic balance between soluble and membrane-bound receptors. The haplotype analyses indicates that allele combinations impacts pre-ART circulating CD4 T-cell counts, immune recovery status and the absolute increment of CD4 T-cell counts. The knowledge about how IL-7/IL-7R axis is related to quantitative CD4 T-cell recovery and immune recovery status after initiating ART could be useful regarding T-cell reservoirs investigations in HIV subjects.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antigen production after latency reversal and expression of inhibitory receptors in CD8+ T cells limit the killing of HIV-1 reactivated cells

  • Ruiz, Alba
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Ouchi, Dan|||0000-0002-8630-152X
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Peña, Ruth
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Goulder, Philip|||0000-0002-9842-4674
  • Barnard, Richard
  • Howell, Bonnie J.
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Prado, Julia G.|||0000-0002-5439-4645
The so-called shock and kill therapies aim to combine HIV-1 reactivation by latency-reversing agents (LRA) with immune clearance to purge the HIV-1 reservoir. The clinical use of LRA has demonstrated detectable perturbations in the HIV-1 reservoir without measurable reductions to date. Consequently, fundamental questions concerning the limitations of the recognition and killing of LRA-reactivated cells by effector cells such as CD8+ T cells remain to be answered. Here, we developed a novel experimental framework where we combine the use of cytotoxic CD8+ T-cell lines and ex vivo CD8+ T cells from HIV-1-infected individuals with functional assays of LRA-inducible reactivation to delineate immune barriers to clear the reservoir. Our results demonstrate the potential for early recognition and killing of reactivated cells by CD8+ T cells. However, the potency of LRAs when crossing the barrier for antigen presentation in target cells, together with the lack of expression of inhibitory receptors in CD8+ T cells, are critical events to maximize the speed of recognition and the magnitude of the killing of LRA-inducible provirus. Taken together, our findings highlight direct limitations in LRA potency and CD8+ T cell functional status to succeed in the cure of HIV-1 infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dendritic Cells From the Cervical Mucosa Capture and Transfer HIV-1 via Siglec-1

  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Cantero, Jon|||0000-0003-4844-6143
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Benet, Susana|||0000-0002-2219-8826
  • Pino, M.
  • Serra-Peinado, Carla|||0000-0003-1413-3990
  • Hernández Gallego, Alba|||0000-0002-4595-468X
  • Castellvi, Josep|||0000-0001-5745-9996
  • Tapia, G.
  • Arnau-Saz, V.
  • Garrido, Joseba M.
  • Tarrats, Antoni|||0000-0002-1276-8522
  • Buzón, Maria José|||0000-0003-4427-9413
  • Martinez-Picado, J.
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
Antigen presenting cells from the cervical mucosa are thought to amplify incoming HIV-1 and spread infection systemically without being productively infected. Yet, the molecular mechanism at the cervical mucosa underlying this viral transmission pathway remains unknown. Here we identified a subset of HLA-DR+ CD14+ CD11c+ cervical DCs at the lamina propria of the ectocervix and the endocervix that expressed the type-I interferon inducible lectin Siglec-1 (CD169), which promoted viral uptake. In the cervical biopsy of a viremic HIV-1+ patient, Siglec-1+ cells harbored HIV-1-containing compartments, demonstrating that in vivo, these cells trap viruses. Ex vivo, a type-I interferon antiviral environment enhanced viral capture and trans-infection via Siglec-1. Nonetheless, HIV-1 transfer via cervical DCs was effectively prevented with antibodies against Siglec-1. Our findings contribute to decipher how cervical DCs may boost HIV-1 replication and promote systemic viral spread from the cervical mucosa, and highlight the importance of including inhibitors against Siglec-1 in microbicidal strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez De Ory, S.
  • Ramos Amador, José Tomás
  • Fortuny Guasch, Claudia
  • González-Tomé, María Isabel
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Moreno Pérez, David|||0000-0002-7017-4095
  • Gavilán, C.
  • Menasalvas, A. I.
  • Piqueras, Ana Isabel
  • Frick, Marie Antoinette|||0000-0002-2553-5090
  • Muñoz-Fernández, M. A.
  • Navarro, Maria Luisa
Background There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection

  • Guillén, Yolanda|||0000-0001-8673-6470
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Rivera Pinto, Javier|||0000-0002-4427-6442
  • Casadellà, Maria|||0000-0002-4115-2305
  • Zevin, Alexander
  • Rocafort, M.
  • Parera, M.
  • Rodríguez Rügnitz, M. Cristina
  • Arumí Rovira, Marçal
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Estany Quera, Carla|||0000-0001-6993-5865
  • Coll, Josep
  • Bravo, Isabel
  • Herrero, Cristina
  • Saz, Jorge|||0000-0002-8679-634X
  • Sirera, Guillem|||0000-0003-4014-9355
  • Torrella Domingo, Adriana|||0000-0003-1848-5096
  • Navarro, Jordi|||0000-0002-7187-0367
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Brander, Christian|||0000-0002-0548-5778
  • Blanco, Julià|||0000-0002-2225-0217
  • Calle, M. Luz|||0000-0001-9334-415X
  • Klatt, N. R.
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Paredes, Roger|||0000-0002-6553-691X
Human immunodeficiency virus (HIV)-1 infection causes severe gut and systemic immune damage, but its effects on the gut microbiome remain unclear. Previous shotgun metagenomic studies in HIV-negative subjects linked low-microbial gene counts (LGC) to gut dysbiosis in diseases featuring intestinal inflammation. Using a similar approach in 156 subjects with different HIV-1 phenotypes, we found a strong, independent, dose-effect association between nadir CD4+ T-cell counts and LGC. As in other diseases involving intestinal inflammation, the gut microbiomes of subjects with LGC were enriched in gram-negative Bacteroides, acetogenic bacteria and Proteobacteria, which are able to metabolize reactive oxygen and nitrogen species; and were depleted in oxygen-sensitive methanogenic archaea and sulfate-reducing bacteria. Interestingly, subjects with LGC also showed increased butyrate levels in direct fecal measurements, consistent with enrichment in Roseburia intestinalis despite reductions in other butyrate producers. The microbiomes of subjects with LGC were also enriched in bacterial virulence factors, as well as in genes associated with beta-lactam, lincosamide, tetracycline, and macrolide resistance. Thus, low nadir CD4+ T-cell counts, rather than HIV-1 serostatus per se, predict the presence of gut dysbiosis in HIV-1 infected subjects. Such dysbiosis does not display obvious HIV-specific features; instead, it shares many similarities with other diseases featuring gut inflammation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa

  • Cantero, Jon|||0000-0003-4844-6143
  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Serra-Peinado, Carla|||0000-0003-1413-3990
  • Rosero, Daniela A.|||0000-0002-3212-2710
  • Luque-Ballesteros, Laura|||0000-0001-9515-5889
  • Astorga-Gamaza, Antonio|||0000-0002-1276-5276
  • Castellvi, Josep|||0000-0001-5745-9996
  • Sanhueza, Tamara
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Lloveras, Belen|||0000-0001-8659-5241
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Prado, Julia G.|||0000-0002-5439-4645
  • Sole Sedeño, Josep Maria|||0000-0002-0789-6896
  • Tarrats, Antoni|||0000-0002-1276-8522
  • Lecumberri, Carla|||0000-0001-6509-5256
  • Mañalich Barrachina, Laura|||0000-0002-4624-4671
  • Centeno Mediavilla, Maria Cristina|||0000-0002-7181-3063
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Buzón, Maria José|||0000-0003-4427-9413
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
HIV viral reservoirs are established very early during infection. Resident memory T cells (T) are present in tissues such as the lower female genital tract, but the contribution of this subset of cells to the pathogenesis and persistence of HIV remains unclear. Here, we show that cervical CD4T display a unique repertoire of clusters of differentiation, with enrichment of several molecules associated with HIV infection susceptibility, longevity and self-renewing capacities. These protein profiles are enriched in a fraction of CD4T expressing CD32. Cervical explant models show that CD4T preferentially support HIV infection and harbor more viral DNA and protein than non-T. Importantly, cervical tissue from ART-suppressed HIV women contain high levels of viral DNA and RNA, being the T fraction the principal contributor. These results recognize the lower female genital tract as an HIV sanctuary and identify CD4T as primary targets of HIV infection and viral persistence. Thus, strategies towards an HIV cure will need to consider T phenotypes, which are widely distributed in tissues.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evolution of the gut microbiome following acute HIV-1 infection

  • Rocafort, Muntsa|||0000-0002-2991-1444
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Rivera Pinto, Javier|||0000-0002-4427-6442
  • Pastor Palomo, Lucía|||0000-0002-8346-514X
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Langhorst, Jost
  • Parera, Mariona|||0000-0002-0756-8307
  • Mandomando, Inacio|||0000-0002-1078-2187
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Urrea, Víctor|||0000-0002-2577-856X
  • Rodríguez Rügnitz, M. Cristina
  • Casadellà, Maria|||0000-0002-4115-2305
  • Calle, M. Luz|||0000-0001-9334-415X
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Blanco, Julià|||0000-0002-2225-0217
  • Naniche, Denise|||0000-0002-4495-6325
  • Paredes, Roger|||0000-0002-6553-691X
In rhesus macaques, simian immunodeficiency virus infection is followed by expansion of enteric viruses but has a limited impact on the gut bacteriome. To understand the longitudinal effects of HIV-1 infection on the human gut microbiota, we prospectively followed 49 Mozambican subjects diagnosed with recent HIV-1 infection (RHI) and 54 HIV-1-negative controls for 9-18 months and compared them with 98 chronically HIV-1-infected subjects treated with antiretrovirals (n = 27) or not (n = 71). We show that RHI is followed by increased fecal adenovirus shedding, which persists during chronic HIV-1 infection and does not resolve with ART. Recent HIV-1 infection is also followed by transient non-HIV-specific changes in the gut bacterial richness and composition. Despite early resilience to change, an HIV-1-specific signature in the gut bacteriome-featuring depletion of Akkermansia, Anaerovibrio, Bifidobacterium, and Clostridium- previously associated with chronic inflammation, CD8+ T cell anergy, and metabolic disorders, can be eventually identified in chronically HIV-1-infected subjects. Recent HIV-1 infection is associated with increased fecal shedding of eukaryotic viruses, transient loss of bacterial taxonomic richness, and long-term reductions in microbial gene richness. An HIV-1-associated microbiome signature only becomes evident in chronically HIV-1-infected subjects. The online version of this article (10.1186/s40168-019-0687-5) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Synonymous genome recoding, a tool to explore microbial biology and new therapeutic strategies

  • Martínez, Miguel Angel
  • Jordan de Paiz, Ana|||0000-0002-3495-7201
  • Franco Cirera, Sandra|||0000-0003-4126-2202
  • Nevot Banús, Maria|||0000-0003-4947-4648
Synthetic genome recoding is a new means of generating designed organisms with altered phenotypes. Synonymous mutations introduced into the protein coding region tolerate modifications in DNA or mRNA without modifying the encoded proteins. Synonymous genome-wide recoding has allowed the synthetic generation of different small-genome viruses with modified phenotypes and biological properties. Recently, a decreased cost of chemically synthesizing DNA and improved methods for assembling DNA fragments (e.g. lambda red recombination and CRISPR-based editing) have enabled the construction of an Escherichia coli variant with a 4-Mb synthetic synonymously recoded genome with a reduced number of sense codons (n = 59) encoding the 20 canonical amino acids. Synonymous genome recoding is increasing our knowledge of microbial interactions with innate immune responses, identifying functional genome structures, and strategically ameliorating cis-inhibitory signaling sequences related to splicing, replication (in eukaryotes), and complex microbe functions, unraveling the relevance of codon usage for the temporal regulation of gene expression and the microbe mutant spectrum and adaptability. New biotechnological and therapeutic applications of this methodology can easily be envisaged. In this review, we discuss how synonymous genome recoding may impact our knowledge of microbial biology and the development of new and better therapeutic methodologies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy

  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Santos, José Ramón|||0000-0002-0886-7114
  • Peña, Ruth
  • Jiménez Moyano, Esther
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Paredes, Roger|||0000-0002-6553-691X
  • Prado, Julia G.|||0000-0002-5439-4645
Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene. From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region and generated clonal virus from plasma samples. We characterized phenotypically clonal variants in terms of replicative capacity and susceptibility to PIs. Also, we used VESPA to identify signature mutations and 3D molecular modelling information to detect conformational changes in the Gag region. All subjects analysed harboured Gag-associated polymorphisms in the absence of resistance mutations in the protease gene. Most Gag changes occurred outside Gag cleavage sites. VESPA analyses identified K95R and R286K (P < 0.01) as signature mutations in Gag present at VF. In one out of four patients with clonal analysis available, we identified clonal variants with high replicative capacity and 8- to 13-fold reduction in darunavir susceptibility. These clonal variants harboured K95R, R286K and additional mutations in Gag. Low susceptibility to darunavir was dependent on the Gag sequence context. All other clonal variants analysed preserved drug susceptibility and virus replicative capacity. Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while preserving viral fitness. This effect is Gag-sequence context dependent and may occur during boosted PI failure.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Urrea, Víctor|||0000-0002-2577-856X
  • Dalmau, Judith|||0000-0001-7513-3711
  • Lopez, Miguel
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Ouchi, Dan|||0000-0002-8630-152X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Passaes, Caroline|||0000-0002-0813-2521
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Saez-Cirion, Asier
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Esteller, M.|||0000-0003-4490-6093
  • Berdasco, Maria|||0000-0002-6750-0400
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
BACKGROUND: Human genetic variation-mostly in the human leukocyte antigen (HLA) and C-C chemokine receptor type 5 (CCR5) regions-explains 25% of the variability in progression of human immunodeficiency virus (HIV) infection. However, it is also known that viral infections can modify cellular DNA methylation patterns. Therefore, changes in the methylation of cytosine-guanine (CpG) islands might modulate progression of HIV infection. METHODS: In total, 85 samples were analyzed: 21 elite controllers (EC), 21 subjects with HIV before combination antiretroviral therapy (cART) (viremic, 93 325 human immunodeficiency virus type 1 [HIV-1] RNA copies/mL) and under suppressive cART (cART, median of 17 months, <50 HIV-1 RNA copies/mL), and 22 HIV-negative donors (HIVneg). We analyzed the methylation pattern of 485 577 CpG in DNA from peripheral CD4+ T lymphocytes. We selected the most differentially methylated gene (TNF) and analyzed its specific methylation, messenger RNA (mRNA) expression, and plasma protein levels in 5 individuals before and after initiation of cART. RESULTS: We observed 129 methylated CpG sites (associated with 43 gene promoters) for which statistically significant differences were recorded in viremic versus HIVneg, 162 CpG sites (55 gene promoters) in viremic versus cART, 441 CpG sites (163 gene promoters) in viremic versus EC, but none in EC versus HIVneg. The TNF promoter region was hypermethylated in viremic versus HIVneg, cART, and EC. Moreover, we observed greater plasma levels of TNF in viremic individuals than in EC, cART, and HIVneg. CONCLUSIONS: Our study shows that genome methylation patterns vary depending on HIV infection status and progression profile and that these variations might have an impact on controlling HIV infection in the absence of cART.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes

  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Yeregui, Elena|||0000-0003-2994-4219
  • Olona, Montserrat|||0000-0001-5303-9361
  • Gutiérrez-Valencia, Alicia|||0000-0003-3445-1574
  • Buzón, Maria José|||0000-0003-4427-9413
  • Martí, Anna
  • Gómez-Bertomeu, Frederic
  • Auguet, Teresa
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Benavent-Bofill, Clara
  • Boqué, Carme
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Mestre, Maria Teresa
  • Vidal, Francesc|||0000-0002-6692-6186
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Permanent control of HIV-1 pathogenesis in exceptional elite controllers, a model of spontaneous cure

  • Casado, Concepcion
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Pernas, María
  • Tarancon-Diez, Laura
  • Rodriguez, Carmen
  • Sanchez-Merino, Víctor
  • Vera, Mar|||0000-0002-3841-7747
  • Olivares, Isabel
  • De Pablo-Bernal, Rebeca
  • Merino-Mansilla, Alberto
  • Del Romero, Jorge
  • Lorenzo-Redondo, Ramon
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Salgado, Maria|||0000-0003-1551-7216
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Lopez-Galindez, Cecilio
Elite controllers (EC) represent a small subset of HIV-1-infected people that spontaneously control viral replication. However, natural virological suppression and absence of immune dysfunction are not always long-term sustained. We define exceptional EC (EEC) as HIV-1 subjects who maintain the EC characteristics without disease progression for more than 25 years. We analyzed three EEC, diagnosed between 1988 and 1992, who never showed signs of clinical disease progression in absence of any antiretroviral treatment. A comprehensive clinical, virological, and immunological study was performed. The individuals simultaneously exhibited ≥3 described host protective alleles, low levels of total HIV-1 DNA (<20 copies/10 6 CD4 + T-cells) without evidence of replication-competent viruses (<0.025 IUPM), consistent with high levels of defective genomes, strong cellular HIV-1-specific immune response, and a high poly-functionality index (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhancement of Antiviral CD8 + T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab

  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Revollo, Boris|||0000-0001-9245-2183
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Manzano, José Luís
  • Boada, Aram|||0000-0001-9809-5308
  • Dalmau, Judith|||0000-0001-7513-3711
  • E. Speiser, Daniel
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • G. Prado, Julia
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
Background: Pembrolizumab is an immune checkpoint inhibitor against programmed cell death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is associated with a diminished functionality in HIV-1 specific-CD8 + T cells. It is thought that PD-1 blockade could contribute to reinvigorate antiviral immunity and reduce the HIV-1 reservoir. Methods: Upon metastatic melanoma diagnosis, an HIV-1-infected individual on stable suppressive antiretroviral regimen was treated with pembrolizumab. A PET-CT was performed before and one year after pembrolizumab initiation. We monitored changes in the immunophenotype and HIV-1 specific-CD8 + T-cell responses during 36 weeks of treatment. Furthermore, we assessed changes in the viral reservoir by total HIV-1 DNA, cell-associated HIV-1 RNA, and ultrasensitive plasma viral load. Results: Complete metabolic response was achieved after pembrolizumab treatment of metastatic melanoma. Activated CD8 + T-cells expressing HLA-DR + /CD38 + transiently increased over the first nine weeks of treatment. Concomitantly, there was an augmented response of HIV-1 specific-CD8 + T cells with TNF production and poly-functionality, transitioning from TNF to an IL-2 profile. Furthermore, a transient reduction of 24% and 32% in total HIV-1 DNA was observed at weeks 3 and 27, respectively, without changes in other markers of viral persistence. Conclusions: These data demonstrate that pembrolizumab may enhance the HIV-1 specific-CD8 + T-cell response, marginally affecting the HIV-1 reservoir. A transient increase of CD8 + T-cell activation, TNF production, and poly-functionality resulted from PD-1 blockade. However, the lack of sustained changes in the viral reservoir suggests that viral reactivation is needed concomitantly with HIV-1-specific immune enhancement.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

  • Medrano, Luz M.
  • Gutiérrez-Rivas, Mónica
  • Blanco, Julià|||0000-0002-2225-0217
  • García, Marcial
  • Jiménez-Sousa, María A.
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Montero, Marta|||0000-0002-3432-5394
  • Iribarren, José Antonio
  • Bernal, Enrique|||0000-0002-4041-0579
  • Martínez, Onofre Juan
  • Benito, José Miguel|||0000-0002-7172-049X
  • Rallón, Norma|||0000-0002-4643-247X
  • Resino, Salvador|||0000-0001-8783-0450
The mitochondrial DNA (mtDNA) seems to influence in a large number of diseases, including HIV infection. Moreover, there is a substantial inter-individual variability in the CD4+ recovery in HIV-infected patients on combination antiretroviral therapy (cART). Our study aimed to analyze the association between mtDNA haplogroups and CD4+ recovery in HIV-infected patients on cART. This is a retrospective study of 324 naïve cART patients with CD4+ < 200 cells/mm 3, who were followed-up during 24 months after initiating cART. All patients had undetectable HIV viral load during the follow-up. Besides, we included 141 healthy controls. MtDNA genotyping was performed by using Sequenom's MassARRAY platform. The primary outcome variable was the slope of CD4+ recovery. Patients were stratified into two groups by the median slope value of CD4+ (9.65 CD4+ cells/mm 3 /month). Logistic regression analyses were performed to calculate the odds of CD4+ recovery according to mtDNA haplogroups. Our study included European HIV-infected patients within the N macro-cluster. The baseline values of CD4+ T-cells were similar between groups of patients stratified by the P50th of the slope of CD4+ T-cells recovery. Patients in the low CD4+ T-cells recovery group were older (p = 0.001), but this variable was included in the multivariate models. When we analyzed the frequencies of mtDNA haplogroups, no significant differences between HIV-infected individuals and healthy controls were found. We did not find any significant association between mtDNA haplogroups and the slope of CD4+ T-cells recovery by linear regression analysis. However, Patients carrying haplogroup H had a higher odds of having a better CD4+ recovery (> 9.65 CD4+ cells/mm 3 /month) than patients without haplogroup H (p = 0.032). The adjusted logistic regression showed that patients carrying haplogroup H had a higher likelihood of achieving a CD4+ recovery > 9.65 CD4+ cells/mm 3 /month [adjusted odds ratio (aOR) = 1.75 (95% CI = 1.04; 2.95); p = 0.035]. European mitochondrial haplogroup H was associated with the improved CD4+ recovery in HIV-infected patients starting cART with CD4+ < 200 cells/mm 3.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Restriction Factors, From Intrinsic Viral Restriction to Shaping Cellular Immunity Against HIV-1

  • Colomer-Lluch, Marta
  • Ruiz, Alba
  • Moris, Arnaud
  • Prado, Julia G.|||0000-0002-5439-4645
Antiviral restriction factors are host cellular proteins that constitute a first line of defense blocking viral replication and propagation. In addition to interfering at critical steps of the viral replication cycle, some restriction factors also act as innate sensors triggering innate responses against infections. Accumulating evidence suggests an additional role for restriction factors in promoting antiviral cellular immunity to combat viruses. Here, we review the recent progress in our understanding on how restriction factors, particularly APOBEC3G, SAMHD1, Tetherin, and TRIM5α have the cell-autonomous potential to induce cellular resistance against HIV-1 while promoting antiviral innate and adaptive immune responses. Also, we provide an overview of how these restriction factors may connect with protein degradation pathways to modulate anti-HIV-1 cellular immune responses, and we summarize the potential of restriction factors-based therapeutics. This review brings a global perspective on the influence of restrictions factors in intrinsic, innate, and also adaptive antiviral immunity opening up novel research avenues for therapeutic strategies in the fields of drug discovery, gene therapy, and vaccines to control viral infections.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors

  • Codoñer, Francisco M.
  • Peña, Ruth
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Pino, Maria
  • Vollbrecht, Thomas
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Draenert, Rika
  • Prado, Julia G.|||0000-0002-5439-4645
Despite the major role of Gag in establishing resistance of HIV-1 to protease inhibitors (PIs), very limited data are available on the total contribution of Gag residues to resistance to PIs. To identify in detail Gag residues and structural interfaces associated with the development of HIV-1 resistance to PIs, we traced viral evolution under the pressure of PIs using Gag-protease single genome sequencing and coevolution analysis of protein sequences in 4 patients treated with PIs over a 9-year period. We identified a total of 38 Gag residues correlated with the protease, 32 of which were outside Gag cleavage sites. These residues were distributed in 23 Gag-protease groups of coevolution, with the viral matrix and the capsid represented in 87% and 52% of the groups. In addition, we uncovered the distribution of Gag correlated residues in specific protein surfaces of the inner face of the viral matrix and at the Cyclophilin A binding loop of the capsid. In summary, our findings suggest a tight interdependency between Gag structural proteins and the protease during the development of resistance of HIV-1 to PIs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

New diagnoses of human immunodeficiency virus infection in the Spanish pediatric HIV Cohort (CoRISpe) from 2004 to 2013

  • Jiménez de Ory, Santiago
  • González-Tomé, María Isabel
  • Fortuny Guasch, Claudia
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Bustillo, Matilde
  • Ramos Amador, José Tomás
  • Muñoz-Fernández, Maria Angeles
  • Navarro, Maria Luisa
Vertical human immunodeficiency virus (HIV) infection has decreased in industrialized countries in recent decades, but there are no studies on the mechanisms of HIV transmission among infected children in Spain. Our aim was to study the characteristics and trends of diagnoses of vertically HIV-infected children in Spain from 2004 to 2013. Vertically HIV-infected children were selected if they were diagnosed from 2004 to 2013, were aged 0 to 18 years old, and were included in the Cohort of the Spanish Pediatric HIV Network (CoRISpe). Demographic, clinical, immunological, and virological data at diagnosis were obtained. The rate of diagnoses of vertically HIV-infected children was calculated as the number of cases per 100,000 inhabitants. Obstetric data of mothers of Spanish children and prophylaxis at childbirth and postpartum were obtained. A total of 218 HIV-infected children were included in the study. Of this sample, 182 children (83.5%) were perinatally HIV infected, and 125 out of those 182 children (68.7%) were born in Spain. The vertically HIV-infected Spanish children were diagnosed earlier and were in better clinical and immunological condition at diagnosis than were foreign children. The rate of vertically HIV-infected children declined from 0.09 in 2004 to 0.03 in 2013 due to the decrease in the rate of children born in Spain (0.08 in 2004 vs 0.01 in 2013). A total of 60 out of 107 mothers (56.1%) of Spanish children were diagnosed at or after childbirth. However, this number declined between 2004 and 2013. The rate of new HIV diagnoses of vertically HIV-infected children decreased significantly between 2004 and 2013 from 0.09 to 0.03 per 100,000 inhabitants.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected Individuals

  • Pastor-Ibáñez, Roque|||0000-0002-0787-4638
  • Blanco-Heredia, Juan|||0000-0001-9526-7450
  • Etcheverry, Florencia
  • Sánchez-Palomino, Sonsoles
  • Díez-Fuertes, Francisco|||0000-0003-2413-9229
  • Casas, Rosa|||0000-0002-0211-9166
  • Navarrete-Muñoz, María Ángeles
  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Lucero, Constanza
  • Fernandez, Irene
  • Leal, Lorna|||0000-0001-7887-6027
  • Benito, José Miguel|||0000-0002-7172-049X
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Paredes, Roger|||0000-0002-6553-691X
  • Rallón, Norma|||0000-0002-4643-247X
  • Estruch, Ramón|||0000-0003-1260-4445
  • Torrents, David|||0000-0002-6086-9037
  • García, Felipe|||0000-0001-7658-5832
Objective: The health effects of a supplemented Mediterranean diet (SMD) with extra-virgin olive oil (EVOO) and nuts are well documented in non-HIV-infected individuals. We hypothesised that the benefits of an SMD could be mediated by changes in the gut microbiota, even in those with an altered intestinal microbiota such as people living with HIV. Design: Individuals living with HIV (n = 102) were randomised to receive an SMD with 50 g/day of EVOO and 30 g/day of walnuts (SMD group) or continue with their regular diet (control group) for 12 weeks. Methods: Adherence to the Mediterranean diet was assessed using the validated 14-item MD-Adherence-Screener (MEDAS) from the PREDIMED study. A sub-study classifying the participants according to their MEDAS scores was performed. Results: The lipid profile was improved in the SMD group vs. that in the control group (delta-total cholesterol and delta-B-lipoprotein). The immune activation (CD4+HLADR+CD38+ and CD8+HLADR+CD38+ cells) and IFN-γ-producing T-cells significantly decreased at week 12 compared to the baseline in the SMD group but not in the control group. The gut microbiota in those from the high-adherence group presented significantly high diversity and richness at the end of the intervention. Succinivibrio and Bifidobacterium abundances were influenced by the adherence to the MD and significantly correlated with Treg cells. Conclusion: The Mediterranean diet improved metabolic parameters, immune activation, Treg function, and the gut microbiota composition in HIV-1-infected individuals. Further, Mediterranean diet increased the Bifidobacterium abundances after the intervention, and it was associated to a beneficial profile.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Tarancon-Diez, Laura
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Arenas, Miguel
  • Alvaro, Tamara
  • Casado, Concepcion
  • Olivares, Isabel
  • Vera, Mar|||0000-0002-3841-7747
  • Rodriguez, Carmen
  • Del Romero, Jorge
  • López-Galíndez, Cecilio|||0000-0002-2324-9584
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Prado, Julia G.|||0000-0002-5439-4645
  • Pernas, María
Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses. The online version contains supplementary material available at 10.1186/s12977-022-00591-7.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis

  • Jesson, Julie|||0000-0002-9461-2520
  • Crichton, Siobhan
  • Quartagno, Matteo
  • Yotebieng, Marcel
  • Abrams, Elaine J.
  • Chokephaibulkit, Kulkanya|||0000-0002-0140-4600
  • Le Coeur, Sophie
  • Aké-Assi, Marie-Hélène
  • Patel, Kunjal|||0000-0003-0002-681X
  • Pinto, Jorge
  • Paul, Mary
  • Vreeman, Rachel
  • Davies, Mary-Ann|||0000-0001-8496-6475
  • Ben-Farhat, Jihane
  • Van Dyke, Russell
  • Judd, Ali|||0000-0003-3176-5295
  • Mofenson, Lynne|||0000-0002-2818-9808
  • Vicari, Marissa
  • Seage, George
  • Bekker, Linda-Gail|||0000-0002-0755-4386
  • Essajee, Shaffiq
  • Gibb, Diana
  • Penazzato, Martina|||0000-0001-5485-8692
  • Collins, Intira Jeannie|||0000-0003-2132-6037
  • Wools-Kaloustian, Kara
  • Slogrove, Amy
  • Powis, Kate|||0000-0002-4478-4471
  • Williams, Paige
  • Matshaba, Mogomotsi
  • Thahane, Lineo
  • Nyasulu, Phoebe
  • Lukhele, Bhekumusa
  • Mwita, Lumumba
  • Kekitiinwa-Rukyalekere, Adeodata
  • Wanless, Sebastian
  • Goetghebuer, Tessa
  • Thorne, Claire
  • Warszawski, Josiane
  • Galli, Luisa|||0000-0002-7912-3366
  • van Rossum, Annemarie M. C.
  • Giaquinto, Carlo
  • Marczynska, Magdalena
  • Marques, Laura
  • Prata, Filipa
  • Ene, Luminita
  • Okhonskaya, Lyuba
  • Navarro, Maria Luisa
  • Frick, Antoinette
  • Naver, Lars
  • Kahlert, Christian|||0000-0002-0784-3276
  • Volokha, Alla|||0000-0003-3092-2228
  • Chappell, Elizabeth|||0000-0003-1053-6434
  • Pape, Jean William
  • Rouzier, Vanessa
  • Marcelin, Adias
  • Succi, Regina
  • Sohn, Annette H.|||0000-0002-0209-3285
  • Kariminia, Azar
  • Edmonds, Andrew
  • Lelo, Patricia
  • Lyamuya, Rita
  • Ogalo, Edith Apondi|||0000-0002-7968-9394
  • Odhiambo, Francesca Akoth
  • Haas, Andreas D.|||0000-0002-4849-181X
  • Bolton, Carolyn|||0000-0001-9103-7746
  • Muhairwe, Josephine
  • Tweya, Hannock
  • Sylla, Mariam
  • D'Almeida, Marceline
  • Renner, Lorna
  • Abzug, Mark J.
  • Oleske, James
  • Purswani, Murli
  • Teasdale, Chloe
  • Nuwagaba-Biribonwoha, Harriet|||0000-0001-5131-3371
  • Goodall, Ruth
  • Leroy, Valériane|||0000-0003-3542-8616
Adolescents living with HIV are subject to multiple co-morbidities, including growth retardation and immunodeficiency. We describe growth and CD4 evolution during adolescence using data from the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) global project. Data were collected between 1994 and 2015 from 11 CIPHER networks worldwide. Adolescents with perinatally acquired HIV infection (APH) who initiated antiretroviral therapy (ART) before age 10 years, with at least one height or CD4 count measurement while aged 10-17 years, were included. Growth was measured using height-for-age Z-scores (HAZ, stunting if <-2 SD, WHO growth charts). Linear mixed-effects models were used to study the evolution of each outcome between ages 10 and 17. For growth, sex-specific models with fractional polynomials were used to model non-linear relationships for age at ART initiation, HAZ at age 10 and time, defined as current age from 10 to 17 years of age. A total of 20,939 and 19,557 APH were included for the growth and CD4 analyses, respectively. Half were females, two-thirds lived in East and Southern Africa, and median age at ART initiation ranged from <3 years in North America and Europe to.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)

  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mur, Isabel|||0000-0001-7660-8483
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Vidal, Francesc|||0000-0002-6692-6186
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
Introduction: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado Kith, Óscar|||0000-0001-8372-2604
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Berenguer, Juan|||0000-0001-8541-8200
  • Medrano, Luz María|||0000-0003-3717-5384
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, María Ángeles|||0000-0002-1945-6169
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Navarro, Jordi|||0000-0002-7187-0367
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Fernández-Rodríguez, Amanda|||0000-0002-5110-2213
  • Resino, Salvador|||0000-0001-8783-0450
Objective: To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods: We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results: HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion: HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Slow progression of pediatric HIV associates with early CD8 + T cell PD-1 expression and a stem-like phenotype

  • Vieira, Vinicius
  • Lim, Nicholas|||0000-0001-9261-7726
  • Singh, Alveera
  • Leitman, Ellen
  • Dsouza, Reena
  • Adland, Emily
  • Muenchhoff, Maximilian|||0000-0001-7016-0470
  • Roider, Julia|||0000-0002-1347-2838
  • Marin Lopez, Miguel
  • Carabelli, Julieta|||0000-0003-2329-3996
  • Giandhari, Jennifer
  • Groll, Andreas|||0000-0001-6787-9118
  • Jooste, Pieter|||0000-0002-8635-2255
  • Prado, Julia G.|||0000-0002-5439-4645
  • Thobakgale, Christina|||0000-0001-5619-8894
  • Dong, Krista|||0000-0002-2038-3518
  • Kiepiela, Photini
  • Prendergast, Andrew J.
  • Tudor-Williams, Gareth|||0000-0002-4488-849X
  • Frater, John|||0000-0001-7163-7277
  • Walker, Bruce D.|||0000-0001-6122-9245
  • Ndung'u, Thumbi|||0000-0003-2962-3992
  • Ramsuran, Veron|||0000-0003-1590-9893
  • Leslie, Alasdair|||0000-0003-2538-6467
  • Kløverpris, Henrik N.|||0000-0002-2165-3313
  • Goulder, Philip|||0000-0002-9842-4674
HIV nonprogression despite persistent viremia is rare among adults who are naive to antiretroviral therapy (ART) but relatively common among ART-naive children. Previous studies indicate that ART-naive pediatric slow progressors (PSPs) adopt immune evasion strategies similar to those described in natural hosts of SIV. However, the mechanisms underlying this immunophenotype are not well understood. In a cohort of early-treated infants who underwent analytical treatment interruption (ATI) after 12 months of ART, expression of PD-1 on CD8 + T cells immediately before ATI was the main predictor of slow progression during ATI. PD-1 + CD8 + T cell frequency was also negatively correlated with CCR5 and HLA-DR expression on CD4 + T cells and predicted stronger HIV-specific T lymphocyte responses. In the CD8 + T cell compartment of PSPs, we identified an enrichment of stem-like TCF-1 + PD-1 + memory cells, whereas pediatric progressors and viremic adults had a terminally exhausted PD-1 + CD39 + population. TCF-1 + PD-1 + expression on CD8 + T cells was associated with higher proliferative activity and stronger Gag-specific effector functionality. These data prompted the hypothesis that the proliferative burst potential of stem-like HIV-specific cytotoxic cells could be exploited in therapeutic strategies to boost the antiviral response and facilitate remission in infants who received early ART with a preserved and nonexhausted T cell compartment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019

  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Berenguer, Juan|||0000-0001-8541-8200
  • Busca, Carmen
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Téllez, María J.
  • Domínguez-Domínguez, Lourdes|||0000-0001-6018-9026
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Navarro, Jordi|||0000-0002-7187-0367
  • Santos, Jesús
  • Morano, Luis
  • Artero, Arturo|||0000-0002-7479-3408
  • Moreno, Javier
  • Rivero-Román, Antonio
  • Santos, Ignacio
  • Giner, Livia|||0000-0002-1885-3736
  • Armiñanzas, Carlos
  • Montero, Marta|||0000-0002-3432-5394
  • Manzardo, Christian
  • Cifuentes, Carmen|||0000-0001-5521-4573
  • García, Coral
  • Galindo Puerto, María José
  • Ferrero, Oscar L.
  • Sanz, José
  • Fuente, Belén Pizarro de la
  • Rodríguez, Carmen
  • Gaspar Alonso-Vega, Gabriel|||0000-0002-7144-8959
  • Pérez, Laura
  • Losa-García, Juan Emilio
  • Force, Lluís
  • Veloso, Sergio
  • Martínez-Alfaro, Elisa
  • Jarrín, Inma|||0000-0002-7485-2252
  • De Miguel, Marta
  • González García, Juan|||0000-0002-3652-002X
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Diez, Cristina
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Corral, Saray
  • Gordillo Gutiérrez, Isabel
  • Ramírez, Margarita
  • Padilla Ortega, Belén
  • López Bernaldo de Quirós, Juan Carlos|||0000-0002-8989-9758
  • Núñez, María José
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Arribas, Jose|||0000-0002-7410-9450
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Busca, Carmen
  • Delgado Hierro, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Martín Carbonero, Luz|||0000-0001-8102-4079
  • Micán-Rivera, R.|||0000-0002-6626-4266
  • Montejano Sanchez, Rocio|||0000-0002-3446-0545
  • Montes, María Luisa|||0000-0003-1748-813X
  • Moreno, Victoria
  • Pérez Valero, Ignacio|||0000-0002-3488-7135
  • Navarro, Carolina
  • Valencia, Eulalia|||0000-0001-6902-0120
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Brieva, Teresa
  • Machuca, Isabel
  • Camacho, Ángela
  • Rivero-Román, Antonio
  • Jarrín, Inma|||0000-0002-7485-2252
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Moreno, Santiago C.
  • Moreno, Antonio V.
  • Casado, José Luis|||0000-0002-7639-8591
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Quereda, Carmen
  • Torrella Domingo, Adriana|||0000-0003-1848-5096
  • Planas, Bibiana|||0000-0002-1490-7127
  • Rodrigo, María José
  • Estrada, Vicente|||0000-0002-7795-5986
  • Vergas, Jorge
  • Téllez, María Jesús
  • Muñoz, Jessica
  • Gutiérrez, Maria Mar
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Ibarguren, Maialen
  • Carmona, María Pilar
  • Rodríguez-Arrondo, Francisco J.
  • Goenaga, Miguel Ángel
  • Azkune, Harkaitz
  • Von Wichmann, Miguel Ángel
  • Iribarren, José Antonio
  • Carmena, Jorge
  • Prado-González, E.
  • Piera-Rojo, G.
  • Ocampo, Antonio
  • Miralles, Celia
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Morano, Luís Enrique
  • Ruiz, Josefa
  • Nuño, Enrique M.
  • Palacios, Rosario
  • Santos, Jésus R.
  • Márquez, Manuel A.
  • Sanz, José N.
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Moreno, Javier A.
  • Arazo, Piedad
  • Tasias, Maria
  • Cuéllar, Sandra
  • Calabuig, Eva|||0000-0002-0177-0037
  • Blanes, Marino
  • Fernández, J.
  • López-Aldeguer, José
  • Salavert, Miguel H.
  • Hernando, Asunción|||0000-0002-1901-1119
  • Domínguez Pérez, Laura|||0000-0001-9540-5112
  • Bisbal, Otilia|||0000-0003-3746-3378
  • De Lagarde, M.
  • Matarranz, Mariano
  • Rubio García, Rafael|||0000-0001-8132-4303
  • Pulido, Federico|||0000-0002-7414-8812
  • Echevarría, Santiago
  • Gutiérrez-Cuadra, Manuel
  • Fariñas, Mª Carmen
  • Reus, Sergio|||0000-0002-3320-9754
  • Merino de Lucas, Esperanza|||0000-0003-3854-4874
  • Boix, Vicente|||0000-0002-7015-3948
  • Torrús-Tendero, Diego
  • Portilla-Tamarit, Irene
  • Pampliega, Maria
  • Díez, Marcos
  • Egea, I.
  • Portilla-Sogorb, Joaquin
  • Ibarra, Sofía E.
  • López, Iñigo
  • De La Peña, Mireia
  • Zubero, Zurinẽ
  • Baraia, Josu B.
  • Muñoz, Josefa G.
  • de Miguel, Julio L.
  • Arranz-Caso, Alberto J.
  • Casas, Esperanza
  • Ferrer, Ana Maria|||0000-0002-3381-9472
  • García, Luis Nm
  • Pérez-Martínez, Laura|||0000-0002-1384-024X
  • Oteo, José A.|||0000-0001-7080-6542
  • Velasco Arribas, Maria|||0000-0001-6554-2095
  • Moreno Nuñez, Leonor
  • Hervás, Rafael
  • Vinuesa, David|||0000-0002-5663-8447
  • Muñoz Medina, Leopoldo|||0000-0001-8995-8271
  • Hernández-Quero, José
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Vidal, Francesc|||0000-0002-6692-6186
  • Silvariño, Rafael
  • Orti, Amat Joaquim
  • Chamarro, Elena
  • Escrig, Cristina
  • Geijo, Paloma
  • Chocarro, Ángel
  • Puerta, Teresa
  • Raposo, Montserrat
  • Vera, Mar|||0000-0002-3841-7747
  • Del Romero, Jorge
  • Bisbe, Josep
  • Teira, Ramon|||0000-0002-0172-564X
  • Vilaró, Josep M.
  • Vegas, Ana
  • Cano Sánchez, Alfredo
  • Alcaraz García, Antonia
  • Muñoz, Ángeles
  • Bernal, Enrique|||0000-0002-4041-0579
  • Campoamor, M. T.
  • Tuya, Maria José
  • Gimeno Gascon, Adelina|||0000-0003-3728-3182
  • Montero-Martínez, Carmen Cecilia Ordoñez
  • Arponen, Sari
  • Barrufet Barqué, Pilar
  • Alonso, Gerardo
  • Toledo, Claudio L.
  • Peláez, Ana I.
  • Lara, G.
  • Consuegra Fernández, Irene
  • Esteban, M.C.
Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain, the ProHEpiC-19 study

  • Violán, Concepció|||0000-0003-3309-5360
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Lamonja-Vicente, Noemí|||0000-0003-1342-1130
  • Carrasco-Ribelles, Lucía Amalia|||0000-0001-9263-1747
  • Chacón, Carla|||0000-0001-8524-6189
  • Manresa, J.M.|||0000-0001-8306-5798
  • Ramos-Roure, Francesc|||0000-0003-2611-8309
  • Dacosta Aguayo, Rosalia|||0000-0003-1861-365X
  • Palacios-Fernández, Cristina
  • Roso-Llorach, Albert|||0000-0002-9264-0405
  • Pujol, Aleix|||0000-0001-6013-9029
  • Ouchi, Dan|||0000-0002-8630-152X
  • Monteagudo, Mònica|||0000-0002-8839-5056
  • Montero-Alía, Pilar|||0000-0002-9823-1485
  • García-Sierra, Rosa|||0000-0001-9220-610X
  • Arméstar, Fernando|||0000-0002-6374-1418
  • Doladé Botías, María|||0000-0001-8263-3087
  • Prat, Nuria
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Boigues Pons, Marc|||0000-0001-6140-2757
  • Moreno, Nemesio|||0000-0002-1617-9549
  • Prado, Julia G.|||0000-0002-5439-4645
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Understanding the immune response to the SARS-CoV-2 virus is critical for efficient monitoring and control strategies. The ProHEpic-19 cohort provides a fine-grained description of the kinetics of antibodies after SARS-CoV-2 infection with an exceptional resolution over 17 months. We established a cohort of 769 healthcare workers including healthy and infected with SARS-CoV-2 in northern Barcelona to determine the kinetics of the IgM against the nucleocapsid (N) and the IgG against the N and spike (S) of SARS-CoV-2 in infected healthcare workers. The study period was from 5 May 2020 to 11 November 2021.We used non-linear mixed models to investigate the kinetics of IgG and IgM measured at nine time points over 17 months from the date of diagnosis. The model included factors of time, gender, and disease severity (asymptomatic, mild-moderate, severe-critical) to assess their effects and their interactions. 474 of the 769 participants (61.6%) became infected with SARS-CoV-2. Significant effects of gender and disease severity were found for the levels of all three antibodies. Median IgM(N) levels were already below the positivity threshold in patients with asymptomatic and mild-moderate disease at day 270 after the diagnosis, while IgG(N and S) levels remained positive at least until days 450 and 270, respectively. Kinetic modelling showed a general rise in both IgM(N) and IgG(N) levels up to day 30, followed by a decay with a rate depending on disease severity. IgG(S) levels remained relatively constant from day 15 over time. IgM(N) and IgG(N, S) SARS-CoV-2 antibodies showed a heterogeneous kinetics over the 17 months. Only the IgG(S) showed a stable increase, and the levels and the kinetics of antibodies varied according to disease severity. The kinetics of IgM and IgG observed over a year also varied by clinical spectrum can be very useful for public health policies around vaccination criteria in adult population. Regional Ministry of Health of the Generalitat de Catalunya (Call COVID19-PoC SLT16_04; NCT04885478). The online version contains supplementary material available at 10.1186/s12879-022-07696-6.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation

  • Masip, Jenifer|||0000-0002-9233-5195
  • Jorba, Rosa|||0000-0003-3307-4340
  • López Dupla, Jesús Miguel|||0000-0002-9141-2523
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Martínez, Esteban|||0000-0002-6911-8846
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Alba, Verónica|||0000-0002-5925-9573
  • Olona, Montserrat|||0000-0001-5303-9361
  • Vidal, Francesc|||0000-0002-6692-6186
  • Gómez-Bertomeu, Frederic
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Nuclear magnetic resonance (NMR)-based advanced lipoprotein tests have demonstrated that LDL and HDL particle numbers (LDL-P and HDL-P) are more powerful cardiovascular (CV) risk biomarkers than conventional cholesterol markers. Of interest, in people living with HIV (PLHIV), predictors of preclinical atherosclerosis and vascular dysfunction may be associated with impaired immune function. We previously stated that immunological non-responders (INR) were at higher CV risk than immunological responders (IR) before starting antiretroviral therapy (ART). Using Liposcale tests, we characterized the lipoprotein profile from the same cohort of PLHIV at month 12 and month 36 after starting ART, intending to explore what happened with these indicators of CV risk during viral suppression. ART initiation dissipates the differences in lipoprotein-based CV risk markers between INR and IR, and only an increase in the number of HDL-P was found in INR + IR when compared to controls (p = 0.047). Interestingly, CD4 T-cell counts negatively correlated with medium HDL-P concentrations at month 12 in all individuals (ρ = -0.335, p = 0.003). Longitudinal analyses showed an important increase in LDL-P and HDL-P at month 36 when compared to baseline values in both IR and INR. A proper balance between a proatherogenic and atherogenic environment may be related to the reconstitution of CD4 T-cell count in PLHIV.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Glycoprotein profile assessed by1h-nmr as a global inflammation marker in patients with HIV infection. A prospective study

  • Malo, Ana-Irene
  • Rull, Anna|||0000-0002-8907-7754
  • Girona, Josefa
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Fuertes-Martín, Rocío
  • Amigó, Núria|||0000-0002-0116-9145
  • Rodríguez-Borjabad, Cèlia
  • Martínez-Micaelo, Neus
  • Leal, Manuel
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Correig, Xavier|||0000-0002-6902-3054
  • Vidal, Francesc|||0000-0002-6692-6186
  • Masana, Luis|||0000-0002-0789-4954
Plasma glycoproteins are a composite biomarker of inflammation and can be detected byH-NMR. The aim of this study was to prospectively appraise the clinical value of plasma glycopro-teins assessed byH-NMR in people living with HIV (PLWH). A total of 221 patients with HIV infection were recruited and studied at baseline and at 48 and 144 weeks. Patients were distributed into two groups according to baseline CD4 T-cell number below or above 200 cells/µL. Patients with fewer than 200 cells/µL were distributed into the responders and nonresponders according to antiretroviral therapy (ART) response at 144 weeks. Glycoprotein concentrations were determined byH-NMR arising from the protein bond N-acetylglucosamine and N-acetylgalactosamine signals (GlycA); and N-acetylneuraminic acid signal (GlycB) associated with the sugar-protein bond con-centration and aggregation state (shapes (height/width)). Basal glycoprotein concentrations were higher in patients with < 200 CD4 T-cell/µL (Glyc A: 1040(917.9-1199.1) vs. 950.4(845.5-1050.9), p < 0.001, and Glyc B: 521(440.3-610.3) vs. 468.6(417.9-507.0) µ mol/L, p < 0.001) being reduced by ART. The height/width (H/W) ratio was the parameter showing a better association with this clinical sta-tus. Baseline glycoproteins predict the condition of responder/nonresponder. In this study,H-NMR glycoproteins provide novel insights to assess inflammation status and have prognostic value in PLWH.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5, Prognostic signature of immune recovery status in treated HIV-positive patients

  • Yeregui, Elena|||0000-0003-2994-4219
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Ceausu, Andra
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Inciarte, Alexy|||0000-0003-1896-3457
  • Vidal-González, Judit
  • Peraire, Maria
  • Perpiñán, Carles|||0000-0003-2398-3276
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Masip, Jenifer|||0000-0002-9233-5195
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Martí, Anna
  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
The underlying mechanisms of incomplete immune reconstitution in treated HIV-positive patients are very complex and may be multifactorial, but perturbation of chemokine secretion could play a key role in CD4 T-cell turnover. We evaluated the circulating baseline and 48-week follow-up concentrations of SDF-1/CXCL12, fractalkine/CX3CL1, MCP-1/CCL2, MIP-α/CCL3, MIP-β/CCL4 and RANTES/CCL5, and we estimated their association with CXCL12, CX3CR1, CCR2, CCL5 and CCR5 single nucleotide polymorphisms (SNPs) to investigate multiple chemokine-chemokine receptor signatures associated with immune dysregulation preceding poor immune recovery. The circulating concentrations and gene expression patterns of SDF-1/CXCL12 (CXCL12 rs1801157) and MCP-1/CCL2 (CCR2 rs1799864_814) were associated with immune recovery status. CCR2 rs1799864_814 and CCR5 rs333_814 (Δ32) determine the baseline plasma RANTES and MIP-α concentrations, respectively, in participants with poor immune response. SDF-1/CXCL12 and MCP-1/CCL2 could be considered prognostic markers of immune failure despite suppressive antiretroviral therapy. The strong linkage disequilibrium (LD) between CCR2 rs1799864_814 and CCR5 rs1800024 indicated that the alleles of each gene are inherited together more often than would be expected by chance. This work was supported by Fondo de Investigacion Sanitaria and SPANISH AIDS Research Network (ISCIII-FEDER); AGAUR and Gilead Fellowship. FV and YMP are supported by grants from the Programa de Intensificación (ISCIII) and Servicio Andaluz de Salud, respectively. JVG,EY and LR are supported by the Instituto de Salud Carlos III (ISCIII). AR is supported by Departament de Salut, Generalitat de Catalunya and by the Instituto de Salud Carlos III (ISCIII).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI), A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

  • Podzamczer, Daniel|||0000-0001-7090-3561
  • Micán-Rivera, R.|||0000-0002-6626-4266
  • Tiraboschi, Juan Manuel|||0000-0002-0073-873X
  • Portilla, J.
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Ribera, E.
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Morano, L.
  • Masiá, M.
  • Gómez, C.
  • Fanjul, F.
  • Payeras, A.
  • Inciarte, Alexy|||0000-0003-1896-3457
  • Estrada, Vicente|||0000-0002-7795-5986
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Castro, A.
  • Bernal, Enrique|||0000-0002-4041-0579
  • Vinuesa, D.
  • Knobel Freud, Hernando|||0000-0003-3186-6416
  • Troya, Jesús|||0000-0001-7323-114X
  • Macías, Juan|||0000-0002-4778-790X
  • Montero, M.
  • Sanz Sanz, Jesús
  • Navarro-Alcaraz, Antonio|||0000-0002-1118-8972
  • Caicedo, A.
  • Fernández Rodríguez, Gonzalo
  • Martínez, Esteban|||0000-0002-6911-8846
  • Moreno, S.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking. Adult (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Von Wichmann, Miguel Ángel
  • Carrero, Ana
  • Yélamos, María Belén
  • Gómez, Julián
  • Resino, Salvador|||0000-0001-8783-0450
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Miralles, Pilar
  • López, Juan Carlos
  • Parras, Francisco José
  • Padilla Ortega, Belén
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Diez, Cristina
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Carretero, S.
  • Bellón, José-María|||0000-0002-8492-1565
  • Bermejo, Javier|||0000-0002-5241-2758
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Pascual Pareja, J. Francisco
  • Zamora, Francisco
  • Peña, Jose M.
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Díaz, Marta
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, Jaime|||0000-0001-6934-4619
  • Bustinduy, M.J.
  • Iribarren, José Antonio
  • Rodríguez-Arrondo, F.
  • Eynde, E.Van den
  • Pérez, M.
  • Ribera, E.
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, A.
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Sanfrutos, M.A.
  • Moreno, S.
  • Quereda, Carmen
  • Arranz, A.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Miguel, J.de
  • Schroeder, S.
  • Vergas, J.
  • Téllez, M.J.
  • Vinuesa, D.
  • Muñoz, Lourdes
  • Hernández Quero, José
  • Ferrer, A.
  • Galindo Puerto, María José
  • Ortiz, L.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Montero, M.
  • Blanes, M.
  • Cuellar, S.
  • Lacruz, José
  • Salavert, Miguel|||0000-0002-8571-2124
  • López-Aldeguer, J.
  • Pérez González, Gustavo|||0000-0001-9112-9042
  • Gaspar, G.
  • Yllescas, M.
  • Crespo, P.
  • Aznar, E.
  • Esteban, H.
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)

  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Canorea, Isabel
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Quereda, Carmen
  • Sanz, José
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Avellón, Ana|||0000-0003-4425-6350
  • Resino, Salvador|||0000-0001-8783-0450
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/mm (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Gómez, Josep|||0000-0002-0573-7621
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Ferrando-Martínez, Sara
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • López-Dupla, Miguel
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Leal, Manuel
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Vidal, Francesc|||0000-0002-6692-6186
  • Rull, Anna|||0000-0002-8907-7754
Dyslipidemia in HIV-infected patients is unique and pathophysiologically associated with host factors, HIV itself and the use of antiretroviral therapy (ART). The use of nuclear magnetic resonance spectroscopy (NMR) provides additional data to conventional lipid measurements concerning the number of lipoprotein subclasses and particle sizes. To investigate the ability of lipoprotein profile, we used a circulating metabolomic approach in a cohort of 103 ART-naive HIV-infected patients, who were initiating non-nucleoside analogue transcriptase inhibitor (NNRTI)-based ART, and we subsequently followed up these patients for 36 months. Univariate and multivariate analyses were performed to evaluate the predictive power of NMR spectroscopy. VLDL-metabolism (including VLDL lipid concentrations, sizes, and particle numbers), total triglycerides and lactate levels resulted in good classifiers of dyslipidemia (AUC 0.903). Total particles/HDL-P ratio was significantly higher in ART-associated dyslipidemia compared to ART-normolipidemia (p = 0.001). Large VLDL-Ps were positively associated with both LDL-triglycerides (ρ 0.682, p < 0.001) and lactate concentrations (ρ 0.416, p < 0.001), the last one a marker of mitochondrial low oxidative capacity. Our data suggest that circulating metabolites have better predictive values for HIV/ART-related dyslipidemia onset than do the biochemical markers associated with conventional lipid measurements. NMR identifies changes in VLDL-P, lactate and LDL-TG as potential clinical markers of baseline HIV-dyslipidemia predisposition. Differences in circulating metabolomics, especially differences in particle size, are indicators of important derangements of mitochondrial function that are linked to ART-related dyslipidemia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human immunodeficiency virus/hepatits C virus coinfection in Spain, Elimination is feasible, but the burden of residual cirrhosis will be significant

  • Berenguer, Juan|||0000-0001-8541-8200
  • Jarrín, Inma|||0000-0002-7485-2252
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Navarro, Jordi|||0000-0002-7187-0367
  • Téllez, María Jesús
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Iribarren, José Antonio
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Márquez, Manuel A.
  • Artero, Arturo|||0000-0002-7479-3408
  • Morano Amado, Luis Enrique|||0000-0002-0560-3260
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Moreno, Javier Marta
  • Fariñas, Mª Carmen
  • Galindo Puerto, María José
  • Hernando, María Asunción
  • Montero, Marta|||0000-0002-3432-5394
  • Cifuentes, Carmen|||0000-0001-5521-4573
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, José Miguel
  • Domíngez, Lourdes
  • Ferrero, Óscar Luis
  • Fuente, Belén Pizarro de la
  • Herrero Rodríguez, Carmen
  • Reus, Sergio|||0000-0002-3320-9754
  • Hernández Quero, José
  • Gaspar Alonso-Vega, Gabriel|||0000-0002-7144-8959
  • Pérez-Martínez, Laura|||0000-0002-1384-024X
  • García, Coral Fernández
  • Force, Lluís
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Losa-García, Juan Emilio
  • Vilaró, Josep M.
  • Bernal, Enrique|||0000-0002-4041-0579
  • Arponen, Sari
  • Ortí, Amat-Joaquim|||0000-0003-3276-7276
  • Chocarro, Ángel
  • Teira, Ramón M.
  • Alonso, Gerardo
  • Silvariño, Rafael
  • Vegas, Ana
  • Geijo, Paloma
  • Bisbe, Josep
  • Esteban, Herminia
  • González García, Juan|||0000-0002-3652-002X
We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

  • Masiá, Mar|||0000-0001-9878-2458
  • Padilla Urrea, Sergio|||0000-0002-8420-7310
  • Moreno, Santiago|||0000-0002-2843-1094
  • Barber, Xavier|||0000-0003-3079-5855
  • Iribarren, Jose A.
  • Del Romero, Jorge
  • Gómez-Sirvent, Juan L.
  • Rivero, María
  • Vidal, Francesc|||0000-0002-6692-6186
  • Campins, Antonio A.
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Del Amo, Julia|||0000-0002-3104-540X
  • Dalmau, David|||0000-0003-1936-478X
  • Navarro, Maria Luisa
  • González, Maria Isabel
  • Soriano, Vicente|||0000-0002-4624-5199
  • Garcia, Federico
  • Rubio, Rafael
  • Iribarren, José Antonio
  • Hernández, Beatriz
  • Berenguer, Juan|||0000-0001-8541-8200
  • Sobrino, Paz
  • Hernando, Victoria
  • Alejos, Belén
  • Álvarez, Débora
  • Monge, Susana|||0000-0003-1412-3012
  • Jarrín, Inma|||0000-0002-7485-2252
  • Rivero, Yaiza
  • González, Cristina
  • Muñoz-Fernández, M.Ängeles
  • García-Merino, Isabel
  • Rico, Coral Gómez
  • de la Fuente, Jorge Gallego
  • Torre, Almudena García
  • Portilla, Joaquín|||0000-0002-3676-9511
  • Merino, Esperanza
  • Reus, Sergio|||0000-0002-3320-9754
  • Boix, Vicente|||0000-0002-7015-3948
  • Giner, Livia|||0000-0002-1885-3736
  • Gadea, Carmen
  • Portilla, Irene
  • Pampliega, Maria
  • Díez, Marcos
  • Rodríguez, Juan Carlos
  • Sánchez Payá, José
  • Podzamczer, Daniel|||0000-0001-7090-3561
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Van Den Eyncle, Evan
  • Di Yacovo, Silvana
  • Sumoy, Maria
  • Gómez, Juan Luis
  • Rodríguez, Patricia
  • Alemán, María Remedios
  • del Mar Alonso, María
  • Hernández, María Inmaculada
  • Díaz-Flores, Felicitas
  • García, Dácil
  • Pelazas, Ricardo
  • Labarga, Pablo
  • Barreiro, Pablo|||0000-0002-3819-5371
  • Rivas, Pablo
  • Blanco, Francisco
  • Carbonero, Luz Martín
  • Vispo, Eugenia
  • Solera, Carmen
  • Asensi, Víctor
  • Valle, Eulalia
  • Cartón, José Antonio
  • Pérez, Vicente Estrada
  • Molina, María Jesús Téllez
  • García, Jorge Vergas
  • Carrera, Elisa Pérez-Cecilia
  • Pulido, Federico|||0000-0002-7414-8812
  • Bisbal, Otilia|||0000-0003-3746-3378
  • Matarranz, Mariano
  • Lagarde, Maria
  • Rubio-Martín, Rafael
  • Hernando, Asunción|||0000-0002-1901-1119
  • Portillo, Angel
  • Arrizabalaga, Julio
  • Aramburu, María José
  • Camino, Xabier
  • Rodríguez-Arrondo, Francisco
  • Von Wichmann, Miguel Ángel
  • Tomé, Lidia Pascual
  • Goenaga, Miguel Ángel
  • Bustinduy, M.J.
  • Galparsoro, H.A.
  • Ibarguren, M.
  • Aguado, Mirian
  • Masiá, M.
  • Fernández, Marta
  • García, Elena
  • Navarro, Andrés
  • Montolio, Fernando
  • Robledano, C.
  • Colomé, J.G.
  • Adsuar, Araceli
  • Pascual, R.
  • Muga, Roberto|||0000-0001-6301-431X
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • López Bernaldo de Quirós, Juan Carlos|||0000-0002-8989-9758
  • Miralles, Pilar
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Padilla Ortega, Belén
  • Gijon, Paloma|||0000-0002-5011-1927
  • Carrero, Ana
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Parras, Francisco José
  • Balsalobre, Pascual
  • Diez, Cristina
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso, S.
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • López-Dupla, M.
  • Olona, Montserrat|||0000-0001-5303-9361
  • Aguilar, Alba
  • Sirvent, J.J.
  • Alba, Verónica|||0000-0002-5925-9573
  • Calavia, O.
  • Montero, M.
  • Lacruz, José
  • Blanes, M.
  • Calabuig, Eva|||0000-0002-0177-0037
  • Cuellar, S.
  • López, J.
  • Salavert, Miguel|||0000-0002-8571-2124
  • González García, Juan|||0000-0002-3652-002X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Peña, Jose M.
  • Arribas, Blanca
  • Castro, Juan Miguel
  • Zamora, Francisco
  • Pérez, I.
  • Estébanez, Miriam
  • García Bujalance, Silvia
  • Díaz, Marta
  • Alcáriz, Natalia Stella
  • Mingorance, Jesús|||0000-0001-6173-5711
  • Montero, Dolores
  • González Baeza, Alicia
  • José, Maria Isabel de
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Sanz Sanz, Jesús
  • Salas, A.
  • Sarriá, C.
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Oteo, José A.|||0000-0001-7080-6542
  • Blanco, José Ramón|||0000-0002-4268-0150
  • Ibarra, V.
  • Metola, L.
  • Sanz, M.
  • Pérez-Martínez, L.
  • Pascual, A.
  • Ramos, C.
  • Arazo, P.
  • Gil, D.
  • Rivero, Montserrat|||0000-0002-5834-1559
  • Casado, M.I.
  • Díaz, J.A.
  • Uriz, J.
  • Repáraz, J.
  • Irigoyen, C.
  • Arraiza, M.J.
  • Segura, Ferrán
  • Amengual Guedan, Maria Jose|||0000-0002-5385-3061
  • Navarro Rubio, Gemma|||0000-0002-7195-9046
  • Sala, Montserrat
  • Cervantes Garcia, Manuel|||0000-0001-6073-1110
  • Pineda, Valentí
  • Segura, Victor
  • Navarro Vilasaro, Marta|||0000-0002-3784-4405
  • Antón, Esperanza
  • Nogueras, Maria-Mercedes|||0000-0001-5925-1929
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, Ana
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • López, D.
  • Gutiérrez, Carolina
  • Madrid, N.
  • Lamas, A.
  • Martí, P.
  • De Diaz, A.
  • Serrrano, S.
  • Donat, Lucas
  • Cano, Amanda|||0000-0001-9567-4283
  • Bernal, Enrique|||0000-0002-4041-0579
  • Muñoz, Á.
  • García, F.
  • Hernández Quero, José
  • Peña, Alejandro
  • Muñoz Medina, Leopoldo|||0000-0001-8995-8271
  • Parra, J.
  • Alvarez, Mar|||0000-0003-4590-4401
  • Chueca, Natalia|||0000-0002-3420-3290
  • Guillot, V.
  • Vinuesa, David|||0000-0002-5663-8447
  • Fernández, J.A.
  • Rodríguez, Carmen
  • Puerta, T.
  • Carrió, J.C.
  • Vera, M.
  • Ballesteros, J.
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sambeat, Maria Antonia
  • Lamarca, Karuna|||0000-0001-5292-2216
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Fernández-Duran, Irene|||0000-0003-1289-7276
  • Antela, A.
  • Losada, E.
  • Riera, M.
  • Peñaranda, María|||0000-0001-6290-3457
  • Leyes, M.
  • Ribas, M.A.
  • Campins, A.A.
  • Vidal, Carmen|||0000-0003-2768-2710
  • Gil, L.
  • Fanjul, F.
  • Marinescu, C.
  • Ribera, Esteban|||0000-0002-3752-8808
  • Santos, J.
  • Márquez, M.
  • Viciana, I.
  • Palacios, Rosario
  • González, C.M.
  • Viciana, P.
  • Leal, Manuel
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Trastoy, M.
  • Espinosa, Nuria|||0000-0003-2249-2352
Outcomes of people living with HIV (PLWH) developing non-AIDS events (NAEs) remain poorly defined. We aimed to classify NAEs according to severity, and to describe clinical outcomes and prognostic factors after NAE occurrence using data from CoRIS, a large Spanish HIV cohort from 2004 to 2013. Prospective multicenter cohort study. Using a multistate approach we estimated 3 transition probabilities: from alive and NAE-free to alive and NAE-experienced ("NAE development"); from alive and NAE-experienced to death ("Death after NAE"); and from alive and NAE-free to death ("Death without NAE"). We analyzed the effect of different covariates, including demographic, immunologic and virologic data, on death or NAE development, based on estimates of hazard ratios (HR). We focused on the transition "Death after NAE". 8,789 PLWH were followed-up until death, cohort censoring or loss to follow-up. 792 first incident NAEs occurred in 9.01% PLWH (incidence rate 28.76; 95% confidence interval [CI], 26.80-30.84, per 1000 patient-years). 112 (14.14%) NAE-experienced PLWH and 240 (2.73%) NAE-free PLWH died. Adjusted HR for the transition "Death after NAE" was 12.1 (95%CI, 4.90-29.89). There was a graded increase in the adjusted HRs for mortality according to NAE severity category: HR (95%CI), 4.02 (2.45-6.57) for intermediate-severity; and 9.85 (5.45-17.81) for serious NAEs compared to low-severity NAEs. Male sex (HR 2.04; 95% CI, 1.11-3.84), age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control

  • Masip, Jenifer|||0000-0002-9233-5195
  • Rallón, Norma|||0000-0002-4643-247X
  • Yeregui, Elena|||0000-0003-2994-4219
  • Olona, Montserrat|||0000-0001-5303-9361
  • Resino, Salvador|||0000-0001-8783-0450
  • Benito, José Miguel|||0000-0002-7172-049X
  • Viladés, Consuelo|||0000-0002-2991-9593
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Alcami, Jose|||0000-0003-0023-7377
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Gómez-Bertomeu, Frederic
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Navarro Vilasaro, Marta|||0000-0002-3784-4405
  • Oteo, José A.|||0000-0001-7080-6542
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Martí, Anna
  • Alba, Verónica|||0000-0002-5925-9573
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Long-term elite controllers (LTECs) are a fascinating small subset of HIV individuals with viral and immunological HIV control in the long term that have been designated as models of an HIV functional cure. However, data on the LTEC phenotype are still scarce, and hence, the metabolomics and lipidomics signatures in the LTEC-extreme phenotype, LTECs with more than 10 years of viral and immunological HIV control, could be pivotal to finding the keys for functional HIV remission. Metabolomics and lipidomics analyses were performed using high-resolution mass spectrometry (ultra-high-performance liquid chromatography-electrospray ionization-quadrupole time of flight [UHPLC-(ESI) qTOF] in plasma samples of 13 patients defined as LTEC-extreme, a group of 20 LTECs that lost viral and/or immunological control during the follow-up study (LTEC-losing) and 9 EC patients with short-term viral and immunological control (less than 5 years; no-LTEC patients). Long-term viral and immunological HIV-1 control was found to be strongly associated with elevated tricarboxylic acid (TCA) cycle function. Interestingly, of the nine metabolites identified in the TCA cycle, α-ketoglutaric acid (p = 0.004), a metabolite implicated in the activation of the mTOR complex, a modulator of HIV latency and regulator of several biological processes, was found to be a key metabolite in the persistent control. On the other hand, a lipidomics panel combining 45 lipid species showed an optimal percentage of separation and an ability to differentiate LTEC-extreme from LTEC-losing, revealing that an elevated lipidomics plasma profile could be a predictive factor for the reignition of viral replication in LTEC individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Adipokines as New Biomarkers of Immune Recovery, Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy

  • Yeregui, Elena|||0000-0003-2994-4219
  • Masip, Jenifer|||0000-0002-9233-5195
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Blanco, Julià|||0000-0002-2225-0217
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Olona, Montserrat|||0000-0001-5303-9361
  • Vidal-González, Judit
  • Peraire, Maria
  • Martí, Anna
  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Gómez-Bertomeu, Fréderic|||0000-0002-8039-2889
  • Leal, Manuel
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
A significant proportion of people living with HIV (PLHIV) who successfully achieve virological suppression fail to recover CD4 T-cell counts. Since adipose tissue has been discovered as a key immune organ, this study aimed to assess the role of adipokines in the HIV immunodiscordant response. This is a multicenter prospective study including 221 PLHIV starting the first antiretroviral therapy (ART) and classified according to baseline CD4 T-cell counts/µL (controls.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

COVID-19 in hospitalized HIV-positive and HIV-negative patients, A matched study

  • Diez, Cristina
  • Del Romero-Raposo, Jorge|||0000-0003-1635-3444
  • Micán-Rivera, R.|||0000-0002-6626-4266
  • López, Juan Carlos
  • Blanco, José Ramón|||0000-0002-4268-0150
  • Calzado, Sonia|||0000-0002-2975-6448
  • Sampériz, Gloria|||0000-0003-0693-2266
  • García-Fraile Fraile, Lucio|||0000-0002-2512-6107
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Gómez-Sirvent, Juan L.
  • Suárez-García, Inés|||0000-0002-7016-716X
  • Amador, Concha|||0000-0003-0843-8624
  • Novella Mena, María
  • Arribas, José Ramón
  • Moreno, Santiago|||0000-0002-2843-1094
  • González García, Juan|||0000-0002-3652-002X
  • Jarrin, Inmaculada
  • Berenguer, Juan|||0000-0001-8541-8200
  • Navarro, Maria Luisa
  • González, Maria Isabel
  • García, Federico
  • Poveda, Eva|||0000-0003-4835-9875
  • Iribarren, José Antonio
  • Rubio, Rafael
  • Alejos, Belén
  • Moreno, Cristina
  • Iniesta, Carlos|||0000-0002-0928-2679
  • Rava, Marta|||0000-0003-2260-9370
  • Izquierdo, Rebeca
  • Muñoz Fernández, María Ángeles
  • Consuegra Fernández, Irene
  • Merino, Esperanza
  • García, Gema
  • Portilla, Irene
  • Agea, Iván
  • Portilla, Joaquín|||0000-0002-3676-9511
  • Sánchez Payá, José
  • Rodríguez, Juan Carlos
  • Gimeno, Lina
  • Giner, Livia|||0000-0002-1885-3736
  • Díez, Marcos
  • Carreres, Melissa
  • Reus, Sergio|||0000-0002-3320-9754
  • Boix, Vicente|||0000-0002-7015-3948
  • Torrús-Tendero, Diego
  • López Lirola, Ana
  • García, Dácil
  • Díaz-Flores, Felicitas
  • Alonso, María del Mar
  • Pelazas, Ricardo
  • Hernández, Jehovana
  • Alemán, María Remedios
  • Hernández, María Inmaculada
  • Asensi, Víctor
  • Valle, Eulalia
  • Rivas Carmenado, María Eugenia
  • Suárez-Zarracina, Tomás
  • Pérez Is, Laura
  • Pulido, Federico|||0000-0002-7414-8812
  • Bisbal, Otilia|||0000-0003-3746-3378
  • Hernando, Asunción|||0000-0002-1901-1119
  • Domínguez-Domínguez, Lourdes|||0000-0001-6018-9026
  • Rial, David
  • Bermejo, Laura
  • Santacreu, Mireia
  • Arrizabalaga, Julio
  • Aramburu, María José
  • Camino, Xabier
  • Rodríguez-Arrondo, Francisco
  • Von Wichmann, Miguel Ángel
  • Pascual Tomé, Lidia
  • Goenaga, Miguel Ángel
  • Bustinduy, Maria Jesús
  • Azkune, Harkaitz
  • Ibarguren, Maialen
  • Lizardi, Aitziber
  • Kortajarena, Xabier
  • Carmona Oyaga, Maria Pilar
  • Umerez Igartua, Maitane
  • Masiá, Mar|||0000-0001-9878-2458
  • Padilla Urrea, Sergio|||0000-0002-8420-7310
  • Robledano, Catalina
  • Colomé, Joan Gregori
  • Adsuar, Araceli
  • Pascual, Rafael
  • Fernández, Marta
  • García, José Alberto
  • Barber, Xavier|||0000-0003-3079-5855
  • Re, Vanessa
  • Garcia Abellán, Javier
  • Pascual Pérez, Reyes
  • Roca, María
  • Muga, Roberto|||0000-0001-6301-431X
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Fuster, Daniel|||0000-0003-1262-5860
  • Gutiérrez, Isabel
  • Ramírez, Margarita
  • Padilla Ortega, Belén
  • Gijon, Paloma|||0000-0002-5011-1927
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Parras, Francisco José
  • Balsalobre, Pascual
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquín
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso, Sergio
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Olona, Montserrat|||0000-0001-5303-9361
  • Rull, Anna|||0000-0002-8907-7754
  • Alba, Verónica|||0000-0002-5925-9573
  • Yeregui, Elena|||0000-0003-2994-4219
  • Masip, Jenifer|||0000-0002-9233-5195
  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Montero, Marta|||0000-0002-3432-5394
  • López-Aldeguer, José
  • Blanes, Marino
  • Tasias Pitarch, María
  • Castro Hernández, Iván
  • Calabuig, Eva|||0000-0002-0177-0037
  • Cuéllar, Sandra
  • Salavert, Miguel|||0000-0002-8571-2124
  • Fernández Navarro, Juan
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Busca, Carmen
  • Cano, Joanna
  • Cardiñanos, Julen
  • Castro, Juan Miguel
  • Delgado Hierro, Ana
  • Escosa García, Luis|||0000-0003-0730-4026
  • Herranz Pinto, Pedro|||0000-0002-9840-6628
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • García Bujalance, Silvia
  • García López-Hortelano, Milagros
  • González Baeza, Alicia
  • Miguel, Rosa de
  • Martín Carbonero, Luz|||0000-0001-8102-4079
  • Mayoral, Mario
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Montejano Sanchez, Rocio|||0000-0002-3446-0545
  • Montes, María Luisa|||0000-0003-1748-813X
  • Moreno, Victoria
  • Pérez Valero, Ignacio|||0000-0002-3488-7135
  • Rúa Cebrián, Guadalupe
  • Rodés, Berta
  • Sainz, Talia|||0000-0002-5301-0945
  • Sendagorta, Elena
  • Valencia, Eulalia|||0000-0001-6902-0120
  • Oteo, José A.|||0000-0001-7080-6542
  • Ibarra, Valvanera
  • Metola, Luis
  • Sanz, Mercedes
  • Pérez-Martínez, Laura|||0000-0002-1384-024X
  • Arazo, Piedad
  • Dalmau, David|||0000-0003-1936-478X
  • Jaén, Angels
  • Sanmartí, Montse
  • Cairó, Mireia|||0000-0003-2386-2765
  • Martinez-Lacasa, Javier
  • Velli, Pablo
  • Font, Roser
  • Martinez, Marina
  • Aiello, Tommaso Francesco|||0000-0003-4441-6318
  • Rivero Marcotegui, Maria
  • Repáraz, Jesús
  • Ruiz de Alda, María Gracia
  • De León Cano, María Teresa
  • Pierola, Beatriz
  • Amengual Guedan, Maria Jose|||0000-0002-5385-3061
  • Navarro Rubio, Gemma|||0000-0002-7195-9046
  • Cervantes Garcia, Manuel|||0000-0001-6073-1110
  • Navarro Vilasaro, Marta|||0000-0002-3784-4405
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Sanz Sanz, Jesús
  • Salas, Ana
  • Sarriá, Cristina
  • Martín Gayo, Enrique|||0000-0002-2619-6086
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, Ana
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Gutiérrez, Carolina
  • Madrid, Nadia
  • del Campo, Santos|||0000-0003-2234-5432
  • Serrano-Villar, Sergio|||0000-0002-5447-3554
  • Vivancos-Gallego, María J.|||0000-0002-9373-6011
  • Martínez Sanz, Javier|||0000-0003-2020-3908
  • Anxa Urroz, Usua
  • Velasco, Tamara
  • Vallejo, Alejandro
  • Bernal, Enrique|||0000-0002-4041-0579
  • Cano Sánchez, Alfredo
  • Alcaráz, Antonia
  • Bravo Urbieta, Joaquín|||0000-0003-2079-0305
  • Muñoz Perez, Ángeles
  • Alcaraz, Maria Jose
  • Villalba, Maria del Carmen
  • Hernández Quero, José
  • Muñoz Medina, Leopoldo|||0000-0001-8995-8271
  • Álvarez, Marta
  • Chueca, Natalia|||0000-0002-3420-3290
  • Vinuesa, David|||0000-0002-5663-8447
  • Martinez-Montes, Clara
  • Guerrero, Carlos
  • de Salazar, Adolfo|||0000-0002-4318-858X
  • Fuentes, Ana
  • Raposo Utrilla, Montserrat
  • Del Romero Guerrero, Jorge|||0000-0001-8922-5182
  • Rodríguez, Carmen
  • Puerta, Teresa
  • Carrió, Juan Carlos
  • Vera, Mar|||0000-0002-3841-7747
  • Ballesteros, Juan
  • Ayerdi, Oskar|||0000-0002-9441-8031
  • Antela, Antonio
  • Losada, Elena
  • Riera, Melchor
  • Peñaranda, María|||0000-0001-6290-3457
  • Ribas, Maria Àngels
  • Campins, Antoni A.
  • Vidal Lampurdanés, Carmen|||0000-0001-5843-8038
  • Fanjul, Francisco
  • Murillas, Javier|||0000-0003-2169-7110
  • Homar, Francisco|||0000-0003-0116-3277
  • Vilchez, Helem H.
  • Martin, Maria Luisa
  • Payeras, Antoni
  • Santos, Jesús
  • Gómez Ayerbe, Cristina
  • Viciana, Isabel
  • Palacios, Rosario
  • Pérez López, Carmen
  • González Domenec, Carmen María
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Espinosa, Nuria|||0000-0003-2249-2352
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Podzamczer, Daniel|||0000-0001-7090-3561
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Tiraboschi, Juan Manuel|||0000-0002-0073-873X
  • Silva, Ana
  • Saumoy, Maria|||0000-0002-0047-1991
  • Prieto, Paula
  • Ribera, Esteban|||0000-0002-3752-8808
  • Curran, Adrian|||0000-0002-1263-0814
  • Olalla, Julian|||0000-0002-8577-3891
  • Pérez Stachowski, Javier|||0000-0002-5189-1953
  • del Arco, Alfonso
  • de la Torre Lima, Javier|||0000-0003-4718-0320
  • Prada, José Luis
  • García de Lomas Guerrero, José María|||0000-0001-8160-8488
  • Martínez, Onofre Juan
  • Vera, Francisco J.
  • Martínez, Lorena
  • García, Josefina
  • Alcaraz, Begoña
  • Jimeno, Amaya
  • Castro, Ángeles
  • Pernas, Berta
  • Mena, Álvaro
  • Muñoz, Josefa
  • Zubero, Miren
  • Baraia-Etxaburu, Josu Mirena
  • Ibarra, Sofia
  • Ferrero, Oscar Luis
  • López de Munain, Josefina
  • Cámara López, Maria Mar
  • De La Peña, Mireia
  • Lopez, Miriam
  • López Azkarreta, Iñigo
  • Galera, Carlos
  • Albendin, Helena
  • Pérez, Aurora
  • Iborra, Asunción
  • Moreno, Antonio
  • Merlos, Maria Angustias
  • Vidal, Asunción
  • Meca, Marisa
  • Pasquau, Francisco
  • Ena, Javier|||0000-0002-1181-7396
  • Benito, Concha
  • Fenoll, Vicenta
  • Gil Anguita, Concepción
  • Algado, José Tomás
  • Malmierca Corral, Eduardo|||0000-0002-4071-7247
  • González-Ruano, Patricia|||0000-0003-0395-7740
  • Martín Rodrigo, Dolores
  • Ruiz Seco, Maria Pilar
  • Omar, Mohamed
  • Gómez Vidal, María Amparo
  • De Zarraga, Miguel Alberto
  • Estrada, Vicente|||0000-0002-7795-5986
  • Téllez, Maria Jesús
  • Vergas, Jorge
  • Pérez-Somarriba, Juncal
  • Górgolas, Miguel
  • Cabello-Ubeda, Alfonso|||0000-0001-8429-8358
  • Álvarez, Beatriz
  • Prieto, Laura
  • Sanz Moreno, José
  • Arranz, Alberto
  • Hernández Gutiérrez, Cristina
  • Galindo Puerto, María José
  • Vilalta, Ramon Fernando
  • Ferrer, Ana Maria|||0000-0002-3381-9472
  • Rivero Román, Antonio|||0000-0002-8643-4250
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • López, Pedro
  • Machuca, Isabel
  • Frias, Mario
  • Camacho, Angela
  • Cervero Jiménez, Miguel|||0000-0001-9387-7917
  • Torres, Rafael
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Rincón, Pilar
  • Macías, Juan|||0000-0002-4778-790X
  • Merchante, Nicolás|||0000-0003-1120-8942
  • Real, Luis M.|||0000-0003-4932-7429
  • Corma Gómez, Anaïs|||0000-0002-1078-0237
  • Fernández Fuertes, Marta
  • Gonzalez-Serna, Alejandro|||0000-0002-0239-8417
  • Pérez González, Alexandre|||0000-0003-4836-6768
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Morano, Luis
  • Miralles, Celia
  • Ocampo Hermida, Antonio|||0000-0002-3176-9758
  • Pousada, Guillermo|||0000-0002-2466-8094
Objectives: We compared the characteristics and clinical outcomes of hospitalized individuals with COVID-19 with [people with HIV (PWH)] and without (non-PWH) HIV co-infection in Spain during the first wave of the pandemic. Methods: This was a retrospective matched cohort study. People with HIV were identified by reviewing clinical records and laboratory registries of 10 922 patients in active-follow-up within the Spanish HIV Research Network (CoRIS) up to 30 June 2020. Each hospitalized PWH was matched with five non-PWH of the same age and sex randomly selected from COVID-19@Spain, a multicentre cohort of 4035 patients hospitalized with confirmed COVID-19. The main outcome was all-cause in-hospital mortality. Results: Forty-five PWH with PCR-confirmed COVID-19 were identified in CoRIS, 21 of whom were hospitalized. A total of 105 age/sex-matched controls were selected from the COVID-19@Spain cohort. The median age in both groups was 53 (Q1-Q3, 46-56) years, and 90.5% were men. In PWH, 19.1% were injecting drug users, 95.2% were on antiretroviral therapy, 94.4% had HIV-RNA < 50 copies/mL, and the median (Q1-Q3) CD4 count was 595 (349-798) cells/μL. No statistically significant differences were found between PWH and non-PWH in number of comorbidities, presenting signs and symptoms, laboratory parameters, radiology findings and severity scores on admission. Corticosteroids were administered to 33.3% and 27.4% of PWH and non-PWH, respectively (P = 0.580). Deaths during admission were documented in two (9.5%) PWH and 12 (11.4%) non-PWH (P = 0.800). Conclusions: Our findings suggest that well-controlled HIV infection does not modify the clinical presentation or worsen clinical outcomes of COVID-19 hospitalization.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Intraepithelial CD15 infiltration identifies high-grade anal dysplasia in people with HIV

  • Mancebo Pérez, Cristina
  • Massana, Nuria
  • Astorga Gamaza, Antonio
  • Burgos, Joaquin
  • Benítez Martínez, Aleix
  • Castellvi, Josep
  • Landolfi, Stefania
  • Curran, Adrian
  • García Pérez, Jorge N.
  • Buzon, Maria Jose
  • Genescà Ferrer, Meritxell
  • Falcó, Vicenç
Adaptive immunity; Immunology; Infectious disease, Immunitat adaptativa; Immunologia; Malaltia infecciosa, Inmunidad adaptativa; Inmunología; Enfermedad infecciosa, Men who have sex with men (MSM) with HIV are at high risk for squamous intraepithelial lesion (SIL) and anal cancer. Identifying local immunological mechanisms involved in the development of anal dysplasia could aid treatment and diagnostics. Here, we studied 111 anal biopsies obtained from 101 MSM with HIV, who participated in an anal screening program. We first assessed multiple immune subsets by flow cytometry, in addition to histological examination, in a discovery cohort. Selected molecules were further evaluated by immunohistochemistry in a validation cohort. Pathological samples were characterized by the presence of resident memory T cells with low expression of CD103 and by changes in natural killer cell subsets, affecting residency and activation. Furthermore, potentially immunosuppressive subsets, including CD15+CD16+ mature neutrophils, gradually increased as the anal lesion progressed. Immunohistochemistry verified the association between the presence of CD15 in the epithelium and SIL diagnosis for the correlation with high-grade SIL. A complex immunological environment with imbalanced proportions of resident effectors and immune-suppressive subsets characterized pathological samples. Neutrophil infiltration, determined by CD15 staining, may represent a valuable pathological marker associated with the grade of dysplasia., The authors thank the study participants. We would also like to thank Cristina de Dios Conde and Marta Valeri Sala from the Microscopy platform at the High Technology Unit (UAT, VHIR) for excellent technical assistance. This work was primarily supported by grants from the Spanish Health Institute Carlos III (ISCIII, PI16/00736 and PI20/00160) and cofunded by ERDF/ESF, “A way to make Europe”/“Investing in your future.” This work was additionally supported in part by the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007), the Fundació La Marató TV3 (201814-10FMTV3), and the Gilead fellowships GLD18/00008. MJB is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). NM was supported by a PhD fellowship from the VHIR. The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez de Ory, Santiago
  • Ramos, José Tomas
  • Fortuny, Clàudia
  • González-Tomé, María Isabel
  • Mellado, Maria José
  • Moreno, David
  • Frick, Marie Antoinette
Retrospective study; Spanish Paediatric HIV Network; Rates of perinatal HIV, Estudio retrospectivo; Red Española de VIH Pediátrico; Tasas de VIH perinatal, Estudi retrospectiu; Xarxa espanyola de VIH Pediàtrica; Taxes de VIH perinatal, Background: There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods: A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results: A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions: A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact., This work has been partially funded by Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de Salud Carlos III (ISCIII) (RD12/0017/0035, RD12/0017/0037 and RD16/0025/0019), project as part of the Plan R+D+I (2008-2011; 2013-2016) and cofinanced by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER), RISEPICLIN-19/2015, Fondo para la Investigación Sanitaria of the Spanish Ministry of Science and Innovation (FIS PI13/00422, PI16/01863), CYTED (214RT0482) and EPIICAL Project. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. COST CA17140 Cancer Nanomedicine-Front The Bench to Bebside. We thank the Spanish HIV HGM BioBank supported by ISC III project RETIC PT13/0010/0028 and PT17/0015/0042. No funding for this work was received from National Institutes of Health (NIH), Wellcome Trust and Howard Hughes Medical Institute (HHMI)
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response

  • Grau Exposito, Judit
  • Navarro Mercadé, Jordi
  • Curran Fàbregas, Adria
  • Planas Ribas, Bibiana
  • Suanzes Diez, Paula
  • Falcó Ferrer, Vicenç
  • Genesca Ferrer, Meritxell
  • Buzón Gómez, María José
  • Astorga Gamaza, Antonio
  • Burgos Cibrian, Joaquin
HIV; Infectious disease; Reservoir, VIH; Malalties infeccioses; Reservori, VIH; Enfermedades infecciosas; Reservorio, Human immunodeficiency virus (HIV) establishes a persistent infection in heterogeneous cell reservoirs, which can be maintained by different mechanisms including cellular proliferation, and represent the main obstacle to curing the infection. The expression of the Fcγ receptor CD32 has been identified as a marker of the active cell reservoirs in people on antiretroviral therapy (ART), but if its expression has any role in conferring advantage for viral persistence is unknown. Here, we report that HIV-infected cells expressing CD32 have reduced susceptibility to natural killer (NK) antibody-dependent cell cytotoxicity (ADCC) by a mechanism compatible with the suboptimal binding of HIV-specific antibodies. Infected CD32 cells have increased proliferative capacity in the presence of immune complexes, and are more resistant to strategies directed to potentiate NK function. Remarkably, reactivation of the latent reservoir from antiretroviral-treated people living with HIV increases the pool of infected CD32 cells, which are largely resistant to the ADCC immune mechanism. Thus, we report the existence of reservoir cells that evade part of the NK immune response through the expression of CD32., This study was supported by the Spanish Secretariat of Science and Innovation and FEDER funds (grants SAF2015-67334-R and RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish “Ministerio de Economia y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI17/01470), GeSIDA and the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 201814-10FMTV3) and the Gilead fellowships GLD19/00084 and GLD18/00008. M.B is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). A.A-G is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016–076382). The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy

  • Gálvez, Cristina
  • Grau Exposito, Judit
  • Urrea, Victor
  • Clotet, Bonaventura
  • Falcó Ferrer, Vicenç
  • Buzón Gómez, María José
ADN del VIH-1; Cura del VIH-1; Reservorio de VIH-1, HIV-1 DNA; HIV-1 cure; HIV-1 reservoir, ADN del VIH-1; Cura del VIH-1; Reservori del VIH-1, Knowing the mechanisms that govern the persistence of infected CD4+ subpopulations could help us to design new therapies to cure HIV-1 infection. We evaluated the simultaneous distribution of the HIV-1 reservoir in 13 CD4+ subpopulations from 14 HIV-1-infected individuals on antiretroviral therapy to analyze its relationship with HIV-1 transcription, immune activation, and cell proliferation. A unique large blood donation was used to isolate CD4, CD4 resting (CD4r), CD4 activated (CD4a), T naive (TN), T stem cell memory (TSCM), T central memory (TCM), T transitional memory (TTM), T effector memory (TEM), circulating T follicular helper (cTFH), TCD20, TCD32, and resting memory TCD2high (rmTCD2high) cells. HIV-1 DNA measured by droplet digital PCR ranged from 3,636 copies/106 in TTM to 244 in peripheral blood mononuclear cells (PBMCs), with no subpopulation standing out for provirus enrichment. Importantly, all the subpopulations harbored intact provirus by intact provirus DNA assay (IPDA). TCD32, cTFH, and TTM had the highest levels of HIV-1 transcription measured by fluorescent in situ hybridization with flow cytometry (FISH/flow), but without reaching statistical differences. The subpopulations more enriched in provirus had a memory phenotype, were less activated (measured by CD38+/HLA-DR+), and expressed more programmed cell death 1 (PD-1). Conversely, subpopulations transcribing more HIV-1 RNA were not necessarily enriched in provirus and were more activated (measured by CD38+/HLA-DR+) and more proliferative (measured by Ki-67). In conclusion, the HIV reservoir is composed of a mosaic of subpopulations contributing to the HIV-1 persistence through different mechanisms such as susceptibility to infection, provirus intactness, or transcriptional status. The narrow range of reservoir differences between the different blood cell subsets tested suggests limited efficacy in targeting only specific cell subpopulations during HIV-1 cure strategies. IMPORTANCE The main barrier for HIV-1 cure is the presence of latently infected CD4+ T cells. Although various cell subpopulations have been identified as major HIV-1 reservoir cells, the relative contribution of infected CD4 subpopulations in the HIV-1 reservoir remains largely unknown. Here, we evaluated the simultaneous distribution of the HIV-1 reservoir in 13 CD4+ T-cell subpopulations in peripheral blood from HIV-1-infected individuals under suppressive antiretroviral therapy. We found that the HIV-1 reservoir is composed of a mosaic of cell subpopulations, with heterogeneous proviral DNA, HIV-1 transcription, and activation status. Hence, each cell subpopulation contributes to the HIV-1 persistence through different mechanisms such as susceptibility to infection, rates of intact provirus, transcriptional status or half-life. This research provides new insights into the composition of the HIV-1 reservoir, suggesting that, to be effective, eradication strategies must simultaneously target multiple cell subpopulations., This work was sponsored in part by Grifols and by Gilead (GLD17/00204). The funding organizations had no input in the design of the study or in the collection, analyses, and interpretation of the data. Similarly, they played no role in the writing of the manuscript or in the decision to submit the study for publication. J.M.-P. is supported by grant PID2019-109870RB-I00 from the Spanish Ministry of Science and Innovation. J.M.-P. and M.J.B. are supported by the RETIC RD16/0025/0041 and RD16/0025/0007 (cofunded by the European Regional Development Fund/European Social Fund). M.J.B. is supported by grant RTI2018-101082-B-I00 (MINECO/FEDER) and by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). C.G. was supported by the Ph.D. fellowship of the Spanish Ministry of Education, Culture, and Sport (FPU15/03698).